[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 206
1. Stolnicu S, Preda O, Dohan M, Puscasiu L, García-Galvis OF, Nogales FF: Pseudoglandular hepatoid differentiation in endometrioid carcinoma of the ovary simulates oxyphilic cell change. Int J Gynecol Pathol; 2008 Oct;27(4):521-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudoglandular hepatoid differentiation in endometrioid carcinoma of the ovary simulates oxyphilic cell change.
  • A 42-year-old patient had a stage III ovarian endometrioid adenocarcinoma with areas of hepatoid carcinoma (HC) of clear cell and eosinophilic pseudoglandular type that was difficult to differentiate from endometrioid carcinoma of oxyphilic type and sex cord-stromal tumor.
  • Immunohistochemically, endometrioid adenocarcinoma was positive for CA125, estrogen and progesterone receptors, CAM5.2, cytokeratin (CK) 7 and 19, and vimentin.
  • HC areas were positive for hep par1, polyclonal carcinoembryonic antigens, CD10, alpha-fetoprotein, epithelial membrane antigens, and antimitochondrial antibodies and shared with endometrioid carcinoma focal CK7, and constant positive CK19, CAM5.2, and progesterone receptors.
  • In the differential diagnosis, a hepatic immunophenotype of oxyphilic, mitochondriae-rich areas (demonstrated by antimitochondrial antibodies) was identified by HC specific (hep par1) and characteristic markers: canalicular, cytoplasmic and membranous polyclonal carcinoembryonic antigens, CD10 patterns, and alpha-fetoprotein).
  • The partial preservation of an endometrioid immunophenotype in HC (positive CK7 and 19 and progesterone receptors) would support an origin from endometrioid carcinoma.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Carcinoma, Hepatocellular / pathology. Cell Differentiation / physiology. Female. Humans. Immunohistochemistry. Oxyphil Cells / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18753970.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


2. Suh I, Vriens MR, Guerrero MA, Griffin A, Shen WT, Duh QY, Clark OH, Kebebew E: Serum thyroglobulin is a poor diagnostic biomarker of malignancy in follicular and Hurthle-cell neoplasms of the thyroid. Am J Surg; 2010 Jul;200(1):41-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum thyroglobulin is a poor diagnostic biomarker of malignancy in follicular and Hurthle-cell neoplasms of the thyroid.
  • We examined whether Tg accurately predicts malignancy in follicular or Hürthle-cell neoplasms.
  • METHODS: We reviewed 366 patients who underwent thyroidectomies for follicular/Hürthle-cell neoplasms.
  • We compared Tg in malignant versus benign tumors by univariate and receiver-operator characteristic analyses.
  • There were no differences between malignant (n = 16) and benign (n = 23) lesions in Tg or any of the normalized indexes.
  • CONCLUSIONS: Tg has poor accuracy for predicting malignancy in follicular or Hürthle-cell thyroid neoplasms.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Adenoma, Oxyphilic / pathology. Thyroglobulin / blood. Thyroid Neoplasms / blood. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. THYROGLOBULIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20637335.001).
  • [ISSN] 1879-1883
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 9010-34-8 / Thyroglobulin
  •  go-up   go-down


3. Katz-Selbst ML, Chhieng DC: Fine-needle aspiration biopsy of recurrent oncocytic carcinoma of parotid gland. Diagn Cytopathol; 2009 Nov;37(11):849-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine-needle aspiration biopsy of recurrent oncocytic carcinoma of parotid gland.
  • His past history was significant for resection of primary oncoctyic carcinoma of the right parotid gland 5 years ago.
  • Fine-needle aspiration biopsy of the right cheek mass was performed and demonstrated oncocytic cells without significant cytologic atypia.
  • On the basis of the past history and comparison of the histology of previously resected specimen, the cytologic impression was consistent with recurrent oncocytic carcinoma of the salivary gland.
  • The cytologic differential diagnosis should include other primary salivary gland neoplasms and metastatic disease.
  • [MeSH-major] Carcinoma / pathology. Neoplasm Recurrence, Local / pathology. Parotid Neoplasms / pathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19526569.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Fonseca E, Soares P, Cardoso-Oliveira M, Sobrinho-Simões M: Diagnostic criteria in well-differentiated thyroid carcinomas. Endocr Pathol; 2006;17(2):109-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic criteria in well-differentiated thyroid carcinomas.
  • The criteria used for the differential diagnosis of well-differentiated thyroid tumors derived from follicular cells are reviewed taking into account the architectural characteristics together with the immunohistochemical and molecular features.
  • The review is focused on follicular carcinoma, papillary carcinoma, follicular variant of papillary carcinoma, and oncocytic (Hürthle cell) tumors, as well as on the recently described borderline lesions: follicular and well-differentiated tumors of uncertain malignant potential, and well-differentiated carcinoma, not otherwise specified.
  • [MeSH-major] Carcinoma / diagnosis. Thyroid Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma, Follicular / classification. Adenocarcinoma, Follicular / diagnosis. Adenocarcinoma, Papillary / classification. Adenocarcinoma, Papillary / diagnosis. Adenoma / classification. Adenoma / diagnosis. Diagnosis, Differential. Humans. Immunohistochemistry

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lab Invest. 1981 Oct;45(4):336-41 [7300245.001]
  • [Cites] Am J Surg Pathol. 2002 Aug;26(8):1016-23 [12170088.001]
  • [Cites] J Pathol. 2005 Jul;206(3):305-11 [15852498.001]
  • [Cites] Int J Surg Pathol. 2000 Jul;8(3):185-189 [11493988.001]
  • [Cites] Virchows Arch. 2000 Aug;437(2):107-15 [10993269.001]
  • [Cites] Endocr Pathol. 1999 Winter;10(4):305-313 [12114767.001]
  • [Cites] Am J Clin Pathol. 2003 Jul;120(1):71-7 [12866375.001]
  • [Cites] Am J Surg Pathol. 2004 Oct;28(10):1336-40 [15371949.001]
  • [Cites] Endocr Pathol. 2002 Spring;13(1):3-16 [12114746.001]
  • [Cites] Int J Surg Pathol. 2005 Jan;13(1):29-35 [15735852.001]
  • [Cites] Virchows Arch. 2004 Jun;444(6):572-6 [15095090.001]
  • [Cites] Histopathology. 2005 Oct;47(4):391-401 [16178894.001]
  • [Cites] Virchows Arch. 2005 Nov;447(5):787-93 [16189702.001]
  • [Cites] Endocr Pathol. 2003 Spring;14(1):55-60 [12746563.001]
  • [Cites] Oncogene. 2003 Jul 17;22(29):4578-80 [12881714.001]
  • [Cites] J Pathol. 2001 Jul;194(3):358-66 [11439369.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Aug;87(8):3947-52 [12161538.001]
  • [Cites] Eur J Cancer. 1997 Feb;33(2):293-6 [9135503.001]
  • [Cites] Am J Clin Pathol. 2002 Jan;117(1):143-50 [11789719.001]
  • [Cites] J Clin Endocrinol Metab. 2003 May;88(5):2318-26 [12727991.001]
  • [Cites] Int J Surg Pathol. 2005 Jul;13(3):235-8 [16086077.001]
  • [Cites] N Engl J Med. 2005 Jun 9;352(23):2406-12 [15944425.001]
  • [Cites] Am J Clin Pathol. 1982 Jan;77(1):20-5 [7055095.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Feb;85(2):878-82 [10690905.001]
  • [Cites] Int J Surg Pathol. 2000 Jul;8(3):181-183 [11493987.001]
  • [Cites] J Clin Invest. 2004 Apr;113(8):1234-42 [15085203.001]
  • [Cites] Science. 2000 Aug 25;289(5483):1357-60 [10958784.001]
  • [Cites] Am J Pathol. 2002 Jun;160(6):2157-67 [12057919.001]
  • [Cites] Am J Pathol. 2002 May;160(5):1857-65 [12000737.001]
  • [Cites] Am J Surg Pathol. 1998 Dec;22(12):1512-20 [9850177.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jan;91(1):213-20 [16219715.001]
  • [Cites] Semin Diagn Pathol. 1985 May;2(2):90-100 [3843693.001]
  • [Cites] Virchows Arch. 2001 Apr;438(4):336-42 [11355166.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Dec;90(12):6373-9 [16174717.001]
  • [Cites] J Pathol. 1998 May;185(1):71-8 [9713362.001]
  • [Cites] Virchows Arch. 2002 Apr;440(4):418-24 [11956824.001]
  • [Cites] Br J Cancer. 2005 May 23;92(10):1892-8 [15841082.001]
  • [Cites] J Pathol. 2004 Feb;202(2):247-51 [14743508.001]
  • [Cites] Int J Surg Pathol. 2003 Oct;11(4):249-51 [14615819.001]
  • [Cites] Endocr Pathol. 2002 Winter;13(4):313-20 [12665649.001]
  • [Cites] Virchows Arch. 2005 Jun;446(6):589-95 [15902486.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Sep;89(9):4267-71 [15356020.001]
  • [Cites] Cancer. 1985 Feb 15;55(4):805-28 [3967175.001]
  • [Cites] Am J Clin Pathol. 1983 Feb;79(2):172-7 [6823901.001]
  • (PMID = 17159243.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 47
  •  go-up   go-down


5. Carling T, Ocal IT, Udelsman R: Special variants of differentiated thyroid cancer: does it alter the extent of surgery versus well-differentiated thyroid cancer? World J Surg; 2007 May;31(5):916-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Recently, more aggressive variants of so-called well-differentiated thyroid carcinomas have been identified such as the tall cell variant, columnar cell variant, diffuse sclerosing variant, insular carcinoma, and Hürthle cell (oncocytic, oxyphilic) carcinomas.
  • The clinical presentation, pathophysiology, diagnosis, and surgical and medical management for these thyroid cancers with intermediate differentiation are discussed.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Adenocarcinoma, Follicular / surgery. Carcinoma, Papillary / pathology. Carcinoma, Papillary / surgery. Thyroid Neoplasms / pathology. Thyroid Neoplasms / surgery

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Diagn Cytopathol. 1997 Jul;17(1):25-9 [9218899.001]
  • [Cites] Pathol Res Pract. 1989 Aug;185(2):200-6 [2798220.001]
  • [Cites] Thyroid. 1998 May;8(5):385-91 [9623728.001]
  • [Cites] Curr Probl Surg. 1994 Dec;31(12):933-1012 [7956323.001]
  • [Cites] Ann Surg. 2001 May;233(5):716-22 [11323510.001]
  • [Cites] Tumori. 2003 Sep-Oct;89(5):529-32 [14870778.001]
  • [Cites] Am J Clin Pathol. 1986 Jan;85(1):77-80 [3940424.001]
  • [Cites] Endocrinol Metab Clin North Am. 1995 Dec;24(4):803-39 [8608780.001]
  • [Cites] Thyroid. 1994 Summer;4(2):233-6 [7920009.001]
  • [Cites] Cancer. 1999 Jul 1;86(1):149-56 [10391575.001]
  • [Cites] Am J Surg Pathol. 1988 Jan;12(1):22-7 [3337337.001]
  • [Cites] World J Surg. 1996 Jan;20(1):88-93 [8588420.001]
  • [Cites] Cancer. 1990 Dec 1;66(11):2306-12 [2245385.001]
  • [Cites] Cancer. 1953 Jan;6(1):57-62 [13009652.001]
  • [Cites] Cancer. 1998 Feb 15;82(4):740-53 [9477108.001]
  • [Cites] Histopathology. 1992 Apr;20(4):360-2 [1577416.001]
  • [Cites] Cleve Clin Q. 1976 WINTER;43(4):207-15 [1000814.001]
  • [Cites] Cancer. 1991 Nov 1;68(9):1944-53 [1913544.001]
  • [Cites] Ann Surg. 1998 Apr;227(4):542-6 [9563543.001]
  • [Cites] Ann Intern Med. 1998 Oct 15;129(8):622-7 [9786809.001]
  • [Cites] Am J Surg Pathol. 1996 Aug;20(8):964-74 [8712296.001]
  • [Cites] Cancer. 2000 Apr 15;88(8):1902-8 [10760768.001]
  • [Cites] Am J Surg Pathol. 1996 Oct;20(10):1205-11 [8827026.001]
  • [Cites] Semin Diagn Pathol. 1985 May;2(2):90-100 [3843693.001]
  • [Cites] World J Surg. 1997 Jan;21(1):15-20; discussion 20-1 [8943172.001]
  • [Cites] J Surg Oncol. 2004 Apr 1;86(1):44-54 [15048680.001]
  • [Cites] Ann Surg. 1998 Sep;228(3):320-30 [9742915.001]
  • [Cites] Diagn Cytopathol. 1999 Jan;20(1):19-23 [9884822.001]
  • [Cites] Am J Surg Pathol. 1984 Sep;8(9):655-68 [6476195.001]
  • [Cites] Langenbecks Arch Surg. 2004 Aug;389(4):278-82 [15164288.001]
  • [Cites] Surg Oncol Clin N Am. 1998 Oct;7(4):645-63 [9735127.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Jan;89(1):91-5 [14715833.001]
  • [Cites] Thyroid. 2005 Jun;15(6):583-7 [16029125.001]
  • [Cites] Ann Surg. 1995 Jul;222(1):101-6 [7618962.001]
  • (PMID = 17345120.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 35
  •  go-up   go-down


6. Sugiyama T, Nakagawa T, Narita M, Nakamura S, Inui M, Tagawa T: Pedunculated oncocytic carcinoma in buccal mucosa: immunohistochemical and ultrastructural studies. Oral Dis; 2006 May;12(3):324-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pedunculated oncocytic carcinoma in buccal mucosa: immunohistochemical and ultrastructural studies.
  • PURPOSE: In this study we evaluated pedunculated oncocytic carcinoma (OC) in the buccal mucosa via immunohistochemical and ultrastructural studies.
  • An incision biopsy revealed the diagnosis of oncocytic tumor, and enucleation was performed.
  • RESULTS: Histopathology results revealed that the tumor consisted of oncocytic cells, characterized by eosinophilic and granular cytoplasm, and atypical nuclei.
  • Electron microscopy revealed numerous dilated cytoplasmic mitochondria, and the cell contours and nucleic shapes of tumor cells were often irregular.
  • CONCLUSIONS: Because the histopathologic features of OC are similar to those of benign oncocytoma, the diagnosis of OC must be confirmed by a combination of clinical and ultrastructural characteristics.
  • [MeSH-major] Adenocarcinoma / pathology. Mouth Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16700744.001).
  • [ISSN] 1354-523X
  • [Journal-full-title] Oral diseases
  • [ISO-abbreviation] Oral Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Mucin-1; 68238-35-7 / Keratins
  •  go-up   go-down


7. Wiseman SM, Melck A, Masoudi H, Ghaidi F, Goldstein L, Gown A, Jones SJ, Griffith OL: Molecular phenotyping of thyroid tumors identifies a marker panel for differentiated thyroid cancer diagnosis. Ann Surg Oncol; 2008 Oct;15(10):2811-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular phenotyping of thyroid tumors identifies a marker panel for differentiated thyroid cancer diagnosis.
  • The objective of this work was to evaluate the molecular phenotype of differentiated thyroid cancer (DTC) and benign thyroid lesions to identify molecular markers that allow for accurate thyroid cancer diagnosis.
  • METHODS: Tissue microarrays consisting of 100 benign and 105 malignant thyroid lesions, plus 24 lymph node samples, were stained for a panel of 57 molecular markers.
  • RESULTS: Of the 57 diagnostic markers evaluated 35 (61%) were significantly associated with a DTC diagnosis after multiple testing correction.
  • The most significant markers for DTC diagnosis were: Galectin-3, Cytokeratin 19, Vascular Endothelial Growth Factor, Androgen Receptor, p16, Aurora-A, and HBME-1.
  • CONCLUSION: Evaluation of the DTC and benign thyroid tumor molecular phenotype has allowed for identification of a marker panel, composed of both established and novel markers, useful for thyroid cancer diagnosis.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma, Follicular / diagnosis. Adenocarcinoma, Follicular / metabolism. Adenoma, Oxyphilic / diagnosis. Adenoma, Oxyphilic / metabolism. Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / metabolism. Cell Differentiation. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Phenotype. Prognosis. Tissue Array Analysis

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18612701.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


8. Musholt PB, Musholt TJ, Morgenstern SC, Worm K, Sheu SY, Schmid KW: Follicular histotypes of oncocytic thyroid carcinomas do not carry mutations of the BRAF hot-spot. World J Surg; 2008 May;32(5):722-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Follicular histotypes of oncocytic thyroid carcinomas do not carry mutations of the BRAF hot-spot.
  • BACKGROUND: The BRAF V600E mutation is the most prevalent genetic aberration in papillary thyroid carcinomas (PTCs), and it is found exclusively in RET/PTC-negative tumors.
  • In oncocytic (Hürthle cell, oxyphilic) thyroid tumors, the presence of RET/PTC rearrangements is associated with either the conventional papillary histotype or the "solid" Hürthle cell tumors, whereas all predominantly follicular oncocytic carcinomas do not harbor RET/PTC chimeras.
  • Although 12% of tumors of the follicular variant of PTC carry BRAF mutations, none of the few oncocytic follicular thyroid adenomas (oncoAd) or carcinomas (oncoFTC) published worldwide tested positive.
  • An aspired molecular-based classification of oncocytic thyroid tumors is in need of additional evidence on BRAF mutations in the follicular histotype.
  • METHODS: A series of 44 oncocytic thyroid tumors with well-documented clinicopathological data was subjected to BRAF mutation analysis (complete exon 15) by automated sequencing.
  • RESULTS: The series of oncocytic thyroid tumors consisted of 21 adenomas (oncoAds: 17 females, 4 males; mean age, 54.5 years; range, 27-80 years), 20 follicular carcinomas (oncoFTCs: 14 females, 6 males; mean age, 61.4 years; range, 39-80 years), and 3 "classic" papillary carcinomas (oncoPTCs: 3 females; mean age, 58.1 years; range, 46-70 years; 3x T2 tumors).
  • The follicular variants of oncocytic cancers are divided into 11x T2, 5x T3, and 4x T4 tumor stages (International Union Against Cancer [UICC] TNM 5th edition).
  • CONCLUSIONS: Our results add to the evidence that, in contrast to follicular variants of oncoPTCs, predominantly follicular oncocytic thyroid tumors harbor neither RET/PTC rearrangements nor BRAF mutations.
  • Furthermore, the findings support the concept that oncocytic neoplasms of the thyroid gland are oncocytic counterparts of the respective histotype (adenoma, FTC, PTC, or poorly differentiated thyroid carcinoma) rather than a separate tumor entity.
  • Molecular characterization of oncocytic thyroid malignancies for RET/PTC or BRAF genetic alterations may help with (preoperative) classification and prognostic evaluation of these tumors.
  • [MeSH-major] Adenocarcinoma, Follicular / genetics. Adenoma, Oxyphilic / genetics. Carcinoma, Papillary / genetics. Mutation. Proto-Oncogene Proteins B-raf / genetics. Thyroid Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Endocrinol (Oxf). 2004 Aug;61(2):239-43 [15272920.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Jan;87(1):364-9 [11788677.001]
  • [Cites] Surgery. 2000 Dec;128(6):984-93 [11114633.001]
  • [Cites] Surgery. 2003 Dec;134(6):881-9; discussion 889 [14668719.001]
  • [Cites] Int J Surg Pathol. 2005 Jan;13(1):29-35 [15735852.001]
  • [Cites] Hum Pathol. 2005 Jun;36(6):694-7 [16021577.001]
  • [Cites] Endocr Relat Cancer. 2007 Jun;14(2):445-52 [17639057.001]
  • [Cites] Endocr J. 2007 Jun;54(3):399-405 [17429154.001]
  • [Cites] Oncogene. 2003 Jul 17;22(29):4578-80 [12881714.001]
  • [Cites] Cancer. 2007 Jul 1;110(1):38-46 [17520704.001]
  • [Cites] Nature. 2002 Jun 27;417(6892):949-54 [12068308.001]
  • [Cites] Endocr Relat Cancer. 2005 Jun;12(2):245-62 [15947100.001]
  • [Cites] J Surg Res. 2007 Dec;143(2):350-63 [17655865.001]
  • [Cites] Eur J Cancer. 2005 Mar;41(5):816-21 [15763659.001]
  • [Cites] Clin Endocrinol (Oxf). 2005 Nov;63(5):588-93 [16268813.001]
  • [Cites] Am J Surg Pathol. 2006 Feb;30(2):216-22 [16434896.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Feb;85(2):878-82 [10690905.001]
  • [Cites] Endocrinology. 2006 Feb;147(2):1014-9 [16254036.001]
  • [Cites] Int J Cancer. 2007 Jan 1;120(1):196-200 [17044028.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1454-7 [12670889.001]
  • [Cites] Endocrinology. 2004 Dec;145(12):5448-51 [15331579.001]
  • [Cites] Endocr Relat Cancer. 2006 Jun;13(2):455-64 [16728573.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Nov;88(11):5399-404 [14602780.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4561-7 [12907632.001]
  • [Cites] Clin Endocrinol (Oxf). 2006 Jan;64(1):105-9 [16402937.001]
  • [Cites] Endocr Relat Cancer. 2006 Jun;13(2):485-95 [16728576.001]
  • [Cites] Endocr Pathol. 2005 Summer;16(2):99-105 [16199894.001]
  • [Cites] Virchows Arch. 2006 Apr;448(4):385-93 [16506015.001]
  • [Cites] Virchows Arch. 2005 Jun;446(6):589-95 [15902486.001]
  • [Cites] Clin Endocrinol (Oxf). 2007 May;66(5):678-83 [17381488.001]
  • [Cites] Mod Pathol. 2007 Jul;20(7):779-87 [17464312.001]
  • [Cites] Adv Anat Pathol. 2001 Nov;8(6):345-54 [11707626.001]
  • (PMID = 18235983.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  •  go-up   go-down


9. Kłubo-Gwieździńska J, Junik R: [The early treatment results of well differentiated thyroid cancer and its dependence on chosen factors]. Endokrynol Pol; 2008 Mar-Apr;59(2):123-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Histological classification revealed 68.1% (62/91) papillary thyroid cancers, 25.3% (23/91) follicular thyroid cancers, and 6.6% (6/91) oxyphilic thyroid cancers.
  • [MeSH-major] Adenocarcinoma, Follicular / therapy. Carcinoma, Papillary / therapy. Thyroid Neoplasms / therapy

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. LEVOTHYROXINE .
  • Hazardous Substances Data Bank. THYROGLOBULIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18465687.001).
  • [ISSN] 0423-104X
  • [Journal-full-title] Endokrynologia Polska
  • [ISO-abbreviation] Endokrynol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 9010-34-8 / Thyroglobulin; Q51BO43MG4 / Thyroxine
  •  go-up   go-down


10. Nix PA, Nicolaides A, Coatesworth AP: Thyroid cancer review 3: management of medullary and undifferentiated thyroid cancer. Int J Clin Pract; 2006 Jan;60(1):80-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In contrast, the rare forms of thyroid cancer which comprise medullary thyroid cancer arising from parafollicluar C cells, Hurthle cell carcinoma, anaplastic carcinoma, thyroid lymphoma and squamous cell carcinoma are typically associated with a poorer survival rate.
  • [MeSH-major] Carcinoma / therapy. Thyroid Neoplasms / therapy
  • [MeSH-minor] Carcinoma, Squamous Cell / diagnosis. Humans. Lymphoma / diagnosis. Neoplasm Staging / methods


11. Lallu S, Naran S, Bethwaite P: Fine needle aspiration cytology of unsuspected metastatic hurthle cell carcinoma of the thyroid and its pitfalls: a report of two cases. Diagn Cytopathol; 2007 Jul;35(7):439-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine needle aspiration cytology of unsuspected metastatic hurthle cell carcinoma of the thyroid and its pitfalls: a report of two cases.
  • We discuss two cases of unsuspected metastatic thyroid carcinoma of Hurthle cell type, presenting as subcutaneous masses in the occipital scalp and supra-acetabular region of the right ilium; clinically suspected to be a lipoma and a vascular tumour, respectively.
  • In case 1, a definitive diagnosis of metastatic Hurthle cell carcinoma was made based on cell block preparation and positive immunohistochemical stains for thyroglobulin and thyroid transcription factor-1.
  • Case 2 was reported as suggesting an oncocytic process, metastatic Hurthle cell lesion.
  • These cases are of interest as the bland cytologic features may lead to an erroneous benign diagnosis.
  • Immunohistochemistry aids the definitive diagnosis of metastatic Hurthle cell carcinoma of thyroid especially when the presence of a previous thyroid lesion is not communicated to the laboratory.
  • [MeSH-major] Adenoma, Oxyphilic / secondary. Biopsy, Fine-Needle. Bone Neoplasms / secondary. Skin Neoplasms / secondary. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17580356.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Historical Article; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Namwongprom S, Núñez RF, Yeung HW, Kim EE, Macapinlac HA: Unusual adrenal metastasis and abdominal carcinomatosis secondary to Hurthle cell carcinoma of the thyroid. Exp Clin Endocrinol Diabetes; 2007 Nov;115(10):694-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual adrenal metastasis and abdominal carcinomatosis secondary to Hurthle cell carcinoma of the thyroid.
  • Hurthle cell carcinoma (HCC) of the thyroid is an uncommon and relatively rare differentiated thyroid neoplasm.
  • [MeSH-major] Abdominal Neoplasms / radiography. Adenoma, Oxyphilic / radiography. Adrenal Gland Neoplasms / radiography. Carcinoma / radiography. Positron-Emission Tomography. Thyroid Neoplasms / radiography

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18058606.001).
  • [ISSN] 0947-7349
  • [Journal-full-title] Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
  • [ISO-abbreviation] Exp. Clin. Endocrinol. Diabetes
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


13. Kuehn A, Paner GP, Skinnider BF, Cohen C, Datta MW, Young AN, Srigley JR, Amin MB: Expression analysis of kidney-specific cadherin in a wide spectrum of traditional and newly recognized renal epithelial neoplasms: diagnostic and histogenetic implications. Am J Surg Pathol; 2007 Oct;31(10):1528-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Kidney-specific cadherin (Ksp-cad) is a membrane-associated cell adhesion glycoprotein expressed by the distal nephron tubular cells in its later developmental stages.
  • Chromophobe renal cell carcinoma and renal oncocytoma are reported to be variably positive for Ksp-cad with some studies suggesting a discriminatory role for Ksp-cad.
  • Immunoreactivity in other tumors with granular eosinophilic cytoplasm including clear cell and papillary renal cell carcinomas needs to be clearly elucidated and its expression in emerging novel and other unusual renal epithelial neoplasm subtypes including tumors with uncertain histogenesis is not yet known.
  • Reactivity with Ksp-cad was observed in the following tumors: chromophobe renal cell carcinoma [23/25 (92%), diffuse (>50% of tumor cells)] positivity and membranous characteristically accentuating the "plant cell-like" histomorphology of the typical (clear) type, renal oncocytoma [15/20 (75%), usually diffuse staining with predominantly membranous accentuation], papillary renal cell carcinoma [5/17 (29%) all focal to moderate, eosinophilic type or type 2-3/7 (43%), basophilic type or type 1-2/10 (20%)], Xp11 translocation carcinoma [1/4 (25%), diffuse positivity] and clear cell renal cell carcinoma [6/36 (17%) all focal, clear cell renal cell carcinoma with prominent eosinophilic cells 1/7 (14%)].
  • Immunoreactivity was higher when evaluating whole histologic sections than with tissue microarrays for both chromophobe renal cell carcinoma (100% vs. 60%) and renal oncocytoma (100% vs. 55%).
  • No immunoreactivity was observed in mucinous tubular and spindle cell carcinomas (0/23), high-grade collecting duct carcinomas (of Bellini) (0/3), renal medullary carcinomas (0/2), and urothelial carcinomas (0/6).
  • The findings argue against the use of Ksp-cad in differentiating chromophobe renal cell carcinoma and renal oncocytomas and further support their relationship to the distal nephron.
  • Ksp-cad may be helpful in distinguishing these two tumor types from clear cell renal cell carcinoma with prominent eosinophilic cells particularly in cases with limited tissue samples (ie, needle core biopsy).
  • In the similar diagnostic setting, caution must be exercised, however, in differentiating chromophobe renal cell carcinoma and renal oncocytoma from the eosinophilic variant of papillary renal cell carcinoma as moderate expression of Ksp-cad may be observed in papillary renal cell carcinoma.
  • The histogenesis of mucinous tubular and spindle cell carcinoma remains debatable as this tumor does not express Ksp-cad, which is highly expressed normally in the thick ascending loop of Henle and the distal convoluted tubules.
  • In conclusion, Ksp-cad is a useful tumor type associated marker for distinguishing chromophobe renal cell carcinoma and renal oncocytoma from the wide range of nonintercalated cell-related adult renal epithelial neoplasms; addition of this marker to a panel comprised of other histologic subtype-associated markers may greatly facilitate histologic subclassification of adult renal epithelial neoplasms.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Cadherins / metabolism. Kidney Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma, Clear Cell / metabolism. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Papillary / metabolism. Adenocarcinoma, Papillary / pathology. Adenoma, Oxyphilic / metabolism. Adenoma, Oxyphilic / pathology. Carcinoma / metabolism. Carcinoma / pathology. Carcinoma, Medullary / metabolism. Carcinoma, Medullary / pathology. Carcinoma, Renal Cell / metabolism. Carcinoma, Renal Cell / pathology. Carcinoma, Transitional Cell / metabolism. Carcinoma, Transitional Cell / pathology. Eosinophilia / metabolism. Eosinophilia / pathology. Humans. Immunoenzyme Techniques. Immunohistochemistry / methods. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17895753.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDH16 protein, human; 0 / Cadherins
  •  go-up   go-down


14. Van den Bruel A, Vauterin T, Poorten VV, Decallonne B: Advances in the medical management of differentiated thyroid carcinoma and their impact on the surgical approach. Acta Chir Belg; 2007 Jun;107(3):271-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advances in the medical management of differentiated thyroid carcinoma and their impact on the surgical approach.
  • [MeSH-major] Adenocarcinoma, Follicular / surgery. Adenocarcinoma, Papillary / surgery. Adenoma, Oxyphilic / surgery. Lymph Node Excision. Practice Guidelines as Topic. Thyroid Neoplasms / surgery. Thyroidectomy

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17685252.001).
  • [ISSN] 0001-5458
  • [Journal-full-title] Acta chirurgica Belgica
  • [ISO-abbreviation] Acta Chir. Belg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Belgium
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 0 / Recombinant Proteins; 9002-71-5 / Thyrotropin
  • [Number-of-references] 20
  •  go-up   go-down


15. Russo P: Partial nephrectomy achieves local tumor control and prevents chronic kidney disease. Expert Rev Anticancer Ther; 2006 Dec;6(12):1745-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / surgery. Adenoma, Oxyphilic / pathology. Adenoma, Oxyphilic / surgery. Carcinoma, Papillary / pathology. Carcinoma, Papillary / surgery. Carcinoma, Renal Cell / pathology. Carcinoma, Renal Cell / surgery. Cardiovascular Diseases / etiology. Cardiovascular Diseases / mortality. Chronic Disease. Humans. Kidney Cortex / surgery. Kidney Diseases / etiology. Kidney Diseases / prevention & control. Kidney Function Tests. Kidney Transplantation. Postoperative Complications / etiology. Postoperative Complications / prevention & control. Tissue Donors. Treatment Outcome

  • Genetic Alliance. consumer health - Kidney Disease.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17181488.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 42
  •  go-up   go-down


16. Mirallié E, Guillan T, Bridji B, Resche I, Rousseau C, Ansquer C, Bodet-Milin C, Curtet C, Carnaille B, Murat A, Charbonnel B, Kraeber-Bodéré F: Therapeutic impact of 18FDG-PET/CT in the management of iodine-negative recurrence of differentiated thyroid carcinoma. Surgery; 2007 Dec;142(6):952-8; discussion 952-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic impact of 18FDG-PET/CT in the management of iodine-negative recurrence of differentiated thyroid carcinoma.
  • BACKGROUND: 18-F-fluoro-2-deoxyglucose positron emission tomography ((18)FDG-PET) is useful in the detection of iodine-negative differentiated thyroid carcinoma (DTC).
  • RESULTS: Forty-five patients (31 women, 14 men), with a mean age of 55 years, with 36 papillary, 5 follicular, and 4 Hürthle carcinomas, were studied.
  • [MeSH-major] Adenocarcinoma, Follicular / radiography. Adenocarcinoma, Follicular / radionuclide imaging. Positron-Emission Tomography / methods. Thyroid Neoplasms / radiography. Thyroid Neoplasms / radionuclide imaging. Tomography, X-Ray Computed
  • [MeSH-minor] Adenoma, Oxyphilic / radiography. Adenoma, Oxyphilic / radionuclide imaging. Adenoma, Oxyphilic / surgery. Adolescent. Adult. Aged. Aged, 80 and over. Cell Differentiation. Female. Fluorodeoxyglucose F18. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / radiography. Neoplasm Recurrence, Local / radionuclide imaging. Patient Selection. Prospective Studies. Radiopharmaceuticals. Thyroglobulin / blood. Thyroidectomy

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. THYROGLOBULIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18063081.001).
  • [ISSN] 1532-7361
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 9010-34-8 / Thyroglobulin
  •  go-up   go-down


17. Marglani O, Alherabi A, Corsten M: Malignant oncocytoma of the lacrimal sac with cervical metastasis: case report and literature review. J Otolaryngol Head Neck Surg; 2008 Feb;37(1):E8-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant oncocytoma of the lacrimal sac with cervical metastasis: case report and literature review.
  • [MeSH-major] Adenoma, Oxyphilic / diagnosis. Eye Neoplasms / diagnosis. Lacrimal Apparatus

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18479617.001).
  • [ISSN] 1916-0216
  • [Journal-full-title] Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale
  • [ISO-abbreviation] J Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Canada
  • [Number-of-references] 20
  •  go-up   go-down


18. Shomaf MS, Younes NA, Albsoul NM, Musmar AA, Al-Zaheri MM, Tarawneh MS, Sroujieh AS: New trends in the clinicopathological features of differentiated thyroid cancer in Central Jordan. Saudi Med J; 2006 Feb;27(2):185-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We analyzed the clinical features, management and outcome of 110 patients diagnosed with thyroid carcinoma at Jordan University Hospital, Amman, between 1996 and 2001.
  • RESULTS: Papillary carcinoma was diagnosed in 87 patients (80%), follicular carcinoma in 3 patients (2.7%), Hurthle cell carcinoma in 8 patients (7.3%), medullary carcinoma in 5 (4.5%), and anaplastic carcinoma in 4 patients (3.6%), metastatic cancer in 2 patients and lymphoma in one patient.
  • All patients with follicular carcinoma were diagnosed in the period 1986-1994.
  • After thyroidectomy and a follow up period of 2-15 years, 10 patients died of their disease, 4 of these died within one year from anaplastic thyroid carcinoma.
  • CONCLUSION: The dramatic decline in the incidence of follicular thyroid carcinoma combined with the increase in the advanced forms of thyroid cancer in Central Jordan may suggest a possible environmental factor in thyroid carcinogenesis in this region.
  • [MeSH-minor] Adult. Aged. Carcinoma / epidemiology. Carcinoma, Medullary / epidemiology. Carcinoma, Papillary / epidemiology. Female. Humans. Jordan / epidemiology. Male. Middle Aged. Neoplasm Metastasis

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16501673.001).
  • [ISSN] 0379-5284
  • [Journal-full-title] Saudi medical journal
  • [ISO-abbreviation] Saudi Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


19. Lai G, Nemolato S, Lecca S, Parodo G, Medda C, Faa G: The role of immunohistochemistry in the diagnosis of hyalinizing clear cell carcinoma of the minor salivary gland: a case report. Eur J Histochem; 2008 Oct-Dec;52(4):251-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of immunohistochemistry in the diagnosis of hyalinizing clear cell carcinoma of the minor salivary gland: a case report.
  • A case of hyalinizing clear cell carcinoma (HCCC) of the minor salivary glands of the oral cavity is reported.
  • These findings confirmed the diagnosis of HCCC of minor salivary glands of the oral cavity.
  • The clinical presentation, the immunohistochemical pattern and the role of cytokeratins in the differential diagnosis of HCCC are discussed with a review of the literature.
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Immunohistochemistry / methods. Salivary Gland Neoplasms / diagnosis. Salivary Glands, Minor / pathology
  • [MeSH-minor] Adenoma, Oxyphilic / diagnosis. Biomarkers, Tumor / analysis. Carcinoma, Mucoepidermoid / diagnosis. Carcinoma, Renal Cell / diagnosis. Carcinoma, Renal Cell / secondary. Diagnosis, Differential. Female. Humans. Hyalin / metabolism. Keratins / analysis. Melanoma / diagnosis. Melanoma / secondary. Middle Aged. Myoepithelioma / diagnosis

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19109100.001).
  • [ISSN] 1121-760X
  • [Journal-full-title] European journal of histochemistry : EJH
  • [ISO-abbreviation] Eur J Histochem
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 68238-35-7 / Keratins
  •  go-up   go-down


20. DeLellis RA: Pathology and genetics of thyroid carcinoma. J Surg Oncol; 2006 Dec 15;94(8):662-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathology and genetics of thyroid carcinoma.
  • Carcinomas of the thyroid comprise a heterogeneous group of neoplasms with distinctive clinical and pathological characteristics.
  • In papillary thyroid carcinoma (PTC), genetic events involve RET and TRK (rearrangements) and BRAF and RAS (mutations), although RAS mutations are uncommon except in the follicular variant of PTC.
  • In contrast, genetic alterations in follicular carcinomas include PAX8-PPARgamma translocations and RAS mutations while mutations of CTNNB1 and p53 have been implicated in the development and progression of poorly differentiated and undifferentiated (anaplastic) thyroid carcinomas.
  • Germline mutations of RET are responsible for the development of heritable forms of medullary thyroid carcinoma (MTC) while somatic mutations of this oncogene are found in a significant proportion of sporadic MTCs.
  • The results of these studies not only have provided additional approaches to thyroid tumor classification, but also have stimulated the development of novel approaches to tumor diagnosis and additional parameters for prognostic assessment and potential biologic therapeutic strategies.
  • [MeSH-major] Adenocarcinoma, Follicular / genetics. Adenocarcinoma, Papillary / genetics. Thyroid Neoplasms / genetics. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adenoma, Oxyphilic / pathology. Carcinoma / pathology. Genes, ras. Humans. Molecular Biology. Multiple Endocrine Neoplasia / genetics. Mutation. PTEN Phosphohydrolase / genetics. Point Mutation. Proto-Oncogene Proteins B-raf / genetics. Proto-Oncogene Proteins c-ret / genetics. Receptor, trkA / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17131411.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Proto-Oncogene Proteins c-ret; EC 2.7.10.1 / Receptor, trkA; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


21. Al-Khatib K, Sieunarine K, Lindsay I, Smith JR: Metastatic Hurthle cell carcinoma in the abdomen masquerading as a primary ovarian tumor: a case report. Int J Gynecol Cancer; 2006 Jan-Feb;16(1):429-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic Hurthle cell carcinoma in the abdomen masquerading as a primary ovarian tumor: a case report.
  • Hurthle cell carcinoma, a variant of follicular carcinoma of the thyroid, has been regarded as an aggressive type of differentiated thyroid cancer.
  • It is diagnosed histologically and regarded as a carcinoma by the presence of vascular invasion or capsular invasion.
  • In this case report, a patient with a history of thyroid Hurthle cell carcinoma presented with what seemingly appeared to be a pelvic mass of gynecological origin, with a raised risk-of-malignancy index of 567.
  • They were diagnosed to be secondary lesions of Hurthle cell carcinoma of the thyroid.
  • Hurthle cell carcinoma of the thyroid has not been known to be associated with the elevation of CA125 nor has it been known to metastasize to the small bowel and sigmoid colon.
  • [MeSH-major] Adenocarcinoma / secondary. Neoplasm Invasiveness / pathology. Ovarian Neoplasms / secondary. Thyroid Neoplasms / pathology
  • [MeSH-minor] Aged. Biopsy, Needle. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Hysterectomy / methods. Immunohistochemistry. Laparotomy / methods. Lymph Nodes / pathology. Ovariectomy / methods. Postmenopause. Risk Assessment. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16445671.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Pusiol T, Franceschetti I, Piscioli I, Beltrame MA, Polce M, Sassi C: Value of imaging and aspiration cytology in the diagnosis of oncocytic carcinoma. Acta Otorhinolaryngol Ital; 2010 Apr;30(2):110-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Value of imaging and aspiration cytology in the diagnosis of oncocytic carcinoma.
  • Oncocytic carcinoma of the parotid gland is a rare neoplasm.
  • To the best of our knowledge the simultaneous occurrence of oncocytic carcinoma and second malignancy in another site (outside the parotid gland) has not been reported.
  • An oncocytic carcinoma of the parotid gland is described in 56-year-old male with simultaneous breast cancer, emphasising the value of aspiration cytology and imaging procedures in the diagnosis of parotideal neoplasms.
  • [MeSH-major] Breast Neoplasms, Male / pathology. Breast Neoplasms, Male / radiography. Carcinoma / pathology. Carcinoma / radiography. Neoplasms, Multiple Primary / pathology. Neoplasms, Multiple Primary / radiography. Parotid Neoplasms / pathology. Parotid Neoplasms / radiography. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Male Breast Cancer.
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Laryngoscope. 2001 Nov;111(11 Pt 1):1989-92 [11801984.001]
  • [Cites] Acta Otolaryngol. 2008 Oct;128(10):1152-8 [18607904.001]
  • [Cites] Ear Nose Throat J. 2003 Sep;82(9):699-701 [14569705.001]
  • [Cites] Acta Cytol. 2003 Nov-Dec;47(6):1099-102 [14674089.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2004 Jun;130(6):773-8 [15210562.001]
  • [Cites] J Laryngol Otol. 1965 Dec;79(12):1064-72 [5858167.001]
  • [Cites] Br J Surg. 1971 Nov;58(11):851-3 [5124858.001]
  • [Cites] Acta Cytol. 1987 May-Jun;31(3):351-6 [3473871.001]
  • [Cites] Radiology. 1987 Oct;165(1):183-9 [3628768.001]
  • [Cites] Diagn Cytopathol. 1991;7(4):420-2 [1935522.001]
  • [Cites] Otolaryngol Head Neck Surg. 1991 Dec;105(6):868-76 [1787978.001]
  • [Cites] Ann Pathol. 1991;11(5-6):359-62 [1804158.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1992 May;118(5):479-82 [1571115.001]
  • [Cites] Indian J Cancer. 1992 Dec;29(4):230-3 [1293011.001]
  • [Cites] Cytopathology. 1994 Apr;5(2):110-3 [8038421.001]
  • [Cites] Diagn Cytopathol. 1994 Dec;11(4):376-9 [7895576.001]
  • [Cites] Cytopathology. 1995 Feb;6(1):54-8 [7734704.001]
  • [Cites] Am J Otolaryngol. 1995 May-Jun;16(3):200-4 [7661319.001]
  • [Cites] Cancer. 1998 Jun 25;84(3):153-9 [9678729.001]
  • [Cites] J Oral Maxillofac Surg. 1999 Mar;57(3):325-8 [10077205.001]
  • [Cites] AMA Arch Pathol. 1953 Apr;55(4):328-46 [13030050.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):20-6 [15668471.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2005 Jul;262(7):567-9 [15592856.001]
  • [Cites] J Otolaryngol. 2006 Jun;35(3):189-92 [16929996.001]
  • [Cites] Onkologie. 2006 Sep;29(8-9):388-90 [16974117.001]
  • [Cites] Br J Plast Surg. 2003 Oct;56(7):637-43 [12969661.001]
  • (PMID = 20559483.001).
  • [ISSN] 1827-675X
  • [Journal-full-title] Acta otorhinolaryngologica Italica : organo ufficiale della Società italiana di otorinolaringologia e chirurgia cervico-facciale
  • [ISO-abbreviation] Acta Otorhinolaryngol Ital
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2882149
  • [Keywords] NOTNLM ; Fine-needle aspiration cytology / Male breast cancer / Malignant tumours / Oncocytic carcinoma / Parotid gland
  •  go-up   go-down


23. Baris O, Mirebeau-Prunier D, Savagner F, Rodien P, Ballester B, Loriod B, Granjeaud S, Guyetant S, Franc B, Houlgatte R, Reynier P, Malthiery Y: Gene profiling reveals specific oncogenic mechanisms and signaling pathways in oncocytic and papillary thyroid carcinoma. Oncogene; 2005 Jun 9;24(25):4155-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene profiling reveals specific oncogenic mechanisms and signaling pathways in oncocytic and papillary thyroid carcinoma.
  • The oncogenic pathways in mitochondrial-rich thyroid carcinomas are not clearly understood.
  • To investigate the possible implication of mitochondrial abundance in the genesis of thyroid tumors, we have explored the gene expression profile of six oncocytic carcinomas and six mitochondrial-rich papillary carcinomas using cDNA-microarray technology.
  • A supervised approach allowed us to identify 83 genes differentially expressed in the two types of carcinoma.
  • Of the 59 genes overexpressed in papillary carcinomas, 51% were involved in cell communication.
  • Of the 24 genes overexpressed in oncocytic carcinomas, 84% were involved in mitochondrial and cellular metabolism.
  • Our results suggest that mitochondrial respiratory chain complexes III and IV play a significant role in the regulation of reactive oxygen species production by oncocytic tumors.
  • [MeSH-major] Carcinoma / genetics. Carcinoma, Papillary / genetics. Gene Expression Profiling / methods. Oncogenes. Signal Transduction / genetics. Thyroid Neoplasms / genetics
  • [MeSH-minor] Actinin / genetics. Cell Communication / genetics. Cytoskeletal Proteins / genetics. Humans. Nitric Oxide Synthase / genetics. Nitric Oxide Synthase Type III. Reverse Transcriptase Polymerase Chain Reaction. alpha Catenin

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15806164.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CTNNA1 protein, human; 0 / Cytoskeletal Proteins; 0 / alpha Catenin; 11003-00-2 / Actinin; EC 1.14.13.39 / NOS3 protein, human; EC 1.14.13.39 / Nitric Oxide Synthase; EC 1.14.13.39 / Nitric Oxide Synthase Type III
  •  go-up   go-down


24. Slough CM, Randolph GW: Workup of well-differentiated thyroid carcinoma. Cancer Control; 2006 Apr;13(2):99-105
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Workup of well-differentiated thyroid carcinoma.
  • BACKGROUND: Well-differentiated thyroid carcinoma (WDTC) includes three main entities: papillary thyroid carcinoma (PTC), follicular thyroid carcinoma (FTC), and Hurthle cell carcinoma (HCC).
  • A thorough knowledge of the natural history and presentation of these carcinomas is vital to the thyroid surgeon.
  • [MeSH-major] Adenocarcinoma, Follicular / diagnosis. Carcinoma, Papillary / diagnosis. Thyroid Neoplasms / diagnosis
  • [MeSH-minor] Biopsy, Fine-Needle. Cell Differentiation. Fluorodeoxyglucose F18. Humans. Magnetic Resonance Imaging. Preoperative Care. Thyroidectomy. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16735983.001).
  • [ISSN] 1073-2748
  • [Journal-full-title] Cancer control : journal of the Moffitt Cancer Center
  • [ISO-abbreviation] Cancer Control
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 72
  •  go-up   go-down


25. Liska J, Altanerova V, Galbavy S, Stvrtina S, Brtko J: Thyroid tumors: histological classification and genetic factors involved in the development of thyroid cancer. Endocr Regul; 2005 Sep;39(3):73-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adenocarcinoma, Follicular / genetics. Adenocarcinoma, Follicular / pathology. Adenoma, Oxyphilic / genetics. Adenoma, Oxyphilic / pathology. Carcinoma / genetics. Carcinoma / pathology. Carcinoma, Medullary / genetics. Carcinoma, Medullary / pathology. Carcinoma, Papillary, Follicular / genetics. Carcinoma, Papillary, Follicular / pathology. DNA, Neoplasm / genetics. Female. Humans. Male. Mutation

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16468229.001).
  • [ISSN] 1210-0668
  • [Journal-full-title] Endocrine regulations
  • [ISO-abbreviation] Endocr Regul
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  • [Number-of-references] 46
  •  go-up   go-down


26. Palmedo H, Bucerius J, Joe A, Strunk H, Hortling N, Meyka S, Roedel R, Wolff M, Wardelmann E, Biersack HJ, Jaeger U: Integrated PET/CT in differentiated thyroid cancer: diagnostic accuracy and impact on patient management. J Nucl Med; 2006 Apr;47(4):616-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study was to investigate the diagnostic accuracy and impact on patient management of the new integrated PET/CT modality in patients with suspected iodine-negative, differentiated thyroid carcinoma (DTC).
  • [MeSH-minor] Adenocarcinoma, Follicular / pathology. Adenocarcinoma, Follicular / radiography. Adenocarcinoma, Follicular / radionuclide imaging. Adenocarcinoma, Papillary / pathology. Adenocarcinoma, Papillary / radiography. Adenocarcinoma, Papillary / radionuclide imaging. Adenoma, Oxyphilic / pathology. Adenoma, Oxyphilic / radiography. Adenoma, Oxyphilic / radionuclide imaging. Adult. Aged. Disease Management. Drug Resistance. Fluorodeoxyglucose F18. Humans. Image Processing, Computer-Assisted. Iodine Radioisotopes / therapeutic use. Lymphatic Metastasis. Middle Aged. Neoplasm Recurrence, Local. Positron-Emission Tomography / methods. Prospective Studies. Radiopharmaceuticals. Thyroglobulin / blood. Tomography, X-Ray Computed. Whole Body Imaging

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. THYROGLOBULIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16595495.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 9010-34-8 / Thyroglobulin
  •  go-up   go-down


27. Pezzolla A, Lattarulo S, Milella M, Barile G, Pascazio B, Ciampolillo A, Fabiano G, Palasciano N: [Incidental carcinoma in thyroid pathology: our experience and review of the literature]. Ann Ital Chir; 2010 May-Jun;81(3):165-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Incidental carcinoma in thyroid pathology: our experience and review of the literature].
  • [Transliterated title] Il carcinoma incidentale nella patologia tiroidea. La nostra esperienza e revisione della letteratura.
  • The diagnosis of incidental thyroid carcinoma in patients submitted to thyroidectomy for a benign disease is quite frequent.
  • A retrospective analysis was performed on 240 patients submitted to surgical intervention in order to establish the incidence of the carcinoma.
  • One hundred sixty five patients (68.75%) were affected by benign disease (132 multinodular goiter, 30 uninodular goiter, 2 Plummer and 1 Basedow) and 75 (31.25%) by carcinoma.
  • In 30 of 165 patients (18.2 %), affected by benign disease, occurred a histological diagnosis of thyroid carcinoma, (18 papillary carcinoma, 6 follicular carcinoma, 5 papillary carcinoma follicular variant and 1 oncocytic carcinoma).
  • In this study it's considered incidental thyroid carcinoma the one occurred in patients who never underwent FNA and there were no suspicious features in all exams that may suggest the presence of carcinoma.
  • Fifteen of the 30 incidental carcinoma (50%) were microcarcinomas; in the other 13, dimensions were more than 1 cm, but less than 2 cm in 9 cases.
  • Two patients had a synchronous carcinoma.
  • This study shows that the only way to put doubts on the real benignity of the disease is the fine needle aspiration; there are no other instruments that could let think about the occurrence of the carcinoma.
  • Moreover in the majority of cases the incidental carcinoma is a microcarcinoma, it doesn't reach significant volume, may be not centered by a FNAB, but in must cases it's not really biologically aggressive.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Carcinoma, Papillary / pathology. Incidental Findings. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adenoma, Oxyphilic / pathology. Adolescent. Adult. Aged. Aged, 80 and over. Biopsy, Fine-Needle. Diagnosis, Differential. Female. Goiter, Nodular / pathology. Graves Disease / pathology. Humans. Incidence. Italy / epidemiology. Male. Middle Aged. Plummer-Vinson Syndrome / pathology. Predictive Value of Tests. Retrospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21105480.001).
  • [ISSN] 0003-469X
  • [Journal-full-title] Annali italiani di chirurgia
  • [ISO-abbreviation] Ann Ital Chir
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Italy
  •  go-up   go-down


28. Blankenship DR, Chin E, Terris DJ: Contemporary management of thyroid cancer. Am J Otolaryngol; 2005 Jul-Aug;26(4):249-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thyroid cancer is a relatively common and frequently curable malignant neoplasm, accounting for nearly 2% of all new cancers diagnosed annually in the United States.
  • In addition to reviewing well-established approaches to diagnosis and management, emphasis is placed on newer techniques, including minimally invasive thyroidectomy, molecular detection of disease propensity, and the use of recombinant thyrotropin prior to radioiodine ablation.
  • [MeSH-minor] Adenocarcinoma, Follicular / diagnosis. Adenocarcinoma, Follicular / pathology. Adenocarcinoma, Follicular / therapy. Adenocarcinoma, Papillary / diagnosis. Adenocarcinoma, Papillary / pathology. Adenocarcinoma, Papillary / therapy. Adenoma, Oxyphilic / diagnosis. Adenoma, Oxyphilic / pathology. Adenoma, Oxyphilic / therapy. Biopsy, Fine-Needle. Carcinoma / diagnosis. Carcinoma / pathology. Carcinoma / therapy. Carcinoma, Medullary / diagnosis. Carcinoma, Medullary / pathology. Carcinoma, Medullary / therapy. Evidence-Based Medicine. Humans. Lymphoma / diagnosis. Lymphoma / pathology. Lymphoma / therapy. Thyroid Gland / anatomy & histology. Thyroid Gland / embryology. Thyroid Gland / radionuclide imaging. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15991091.001).
  • [ISSN] 0196-0709
  • [Journal-full-title] American journal of otolaryngology
  • [ISO-abbreviation] Am J Otolaryngol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 90
  •  go-up   go-down


29. Rubio V, Tamarit JM, Baviera N, Fernández S, Estrems P, Seijas T, López C, Dalmau J: [Methodology for evaluation of malignancy screening in surgical thyroid gland disease]. Acta Otorrinolaringol Esp; 2009 Nov-Dec;60(6):390-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Evaluación metodológica para detección de malignidad en patología quirúrgica tiroidea.
  • The specific sensitivities towards papillary carcinoma of FNA and extemporaneous biopsy were 81% and 88%, whilst for follicular carcinoma they were 66% and 62.5%, respectively.
  • CONCLUSIONS: FNA has good sensitivity in clinical suspicion of thyroid papillary carcinoma, although it should be complemented by extemporaneous biopsy due to its better specificity.
  • In the case of follicular carcinoma there is a tendency towards conservative treatment, without carrying out extemporaneous biopsy previously and with reintervention in case of definitive malignancy.
  • [MeSH-major] Adenocarcinoma, Follicular / diagnosis. Adenoma / diagnosis. Carcinoma, Papillary / diagnosis. Thyroid Neoplasms / diagnosis
  • [MeSH-minor] Adenoma, Oxyphilic / diagnosis. Adenoma, Oxyphilic / pathology. Adenoma, Oxyphilic / radionuclide imaging. Adenoma, Oxyphilic / surgery. Adenoma, Oxyphilic / ultrasonography. Adolescent. Adult. Aged. Aged, 80 and over. Biopsy / methods. Biopsy, Fine-Needle. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Palpation. Predictive Value of Tests. Retrospective Studies. Sensitivity and Specificity. Thyroid Diseases / diagnosis. Thyroid Diseases / pathology. Thyroid Diseases / radionuclide imaging. Thyroid Diseases / ultrasonography. Thyroidectomy. Young Adult

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19850274.001).
  • [ISSN] 1988-3013
  • [Journal-full-title] Acta otorrinolaringológica española
  • [ISO-abbreviation] Acta Otorrinolaringol Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


30. Mwandila M, Waller H, Stott V, Mercer P: A case of a testosterone-secreting oncocytic adrenocortical carcinoma. N Z Med J; 2010 Nov 5;123(1325):80-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of a testosterone-secreting oncocytic adrenocortical carcinoma.
  • Oncocytic neoplasms are most rarely found in the adrenal gland.
  • We present a case of a testosterone-secreting oncocytic adrenocortical carcinoma in a 19-year-old female who presented with acne, hirsutism and irregular menses.
  • The histology showed the tumour to be comprised of oncocytic cells with granular, eosinophilic cytoplasm, features consistent with an oncocytic carcinoma.
  • This is the first case presented of a testosterone-secreting oncocytic adrenocortical carcinoma.
  • [MeSH-major] Adrenal Cortex Neoplasms / secretion. Adrenocortical Carcinoma / secretion. Testosterone / secretion
  • [MeSH-minor] Adrenalectomy / methods. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Laparoscopy. Tomography, X-Ray Computed. Young Adult

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21317966.001).
  • [ISSN] 1175-8716
  • [Journal-full-title] The New Zealand medical journal
  • [ISO-abbreviation] N. Z. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 3XMK78S47O / Testosterone
  •  go-up   go-down


31. Colella G, Apicella A, Bove P, Rossiello L, Trodella M, Rossiello R: Oncocytic carcinoma of the accessory lobe of the parotid gland. J Craniofac Surg; 2010 Nov;21(6):1987-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncocytic carcinoma of the accessory lobe of the parotid gland.
  • Oncocytic carcinoma is a rare tumor of the parotid gland.
  • The clinical and histologic difficulties in relationship to the diagnosis of a midcheek mass consisting of an unusual tumor are emphasized.
  • [MeSH-major] Adenocarcinoma / diagnosis. Parotid Neoplasms / diagnosis
  • [MeSH-minor] Aged. Biopsy, Fine-Needle. Cheek / pathology. Diagnosis, Differential. Follow-Up Studies. Humans. Lymphatic Metastasis / pathology. Male. Masseter Muscle / pathology. Oxyphil Cells / pathology. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21119478.001).
  • [ISSN] 1536-3732
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Fukuda D, Ikematsu H, Kojima M, Oono Y, Kojima T, Minashi K, Yano T, Ochiai A, Kaneko K: Early oncocytic adenocarcinoma of the transverse colon. Endoscopy; 2010;42 Suppl 2:E261-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early oncocytic adenocarcinoma of the transverse colon.
  • [MeSH-major] Adenocarcinoma / pathology. Colonic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20931473.001).
  • [ISSN] 1438-8812
  • [Journal-full-title] Endoscopy
  • [ISO-abbreviation] Endoscopy
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


33. Caloglu M, Yurut-Caloglu V, Altaner S, Huseyinova G, Unlu E, Karagol H, Uzal C: Oncocytic carcinoma of the parotid gland. Onkologie; 2006 Sep;29(8-9):388-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncocytic carcinoma of the parotid gland.
  • BACKGROUND: Oncocytic carcinoma is a rare tumor of major salivary glands.
  • Histochemical or electron microscopic confirmation of the oncocytic nature of the tumor cell is needed for differential diagnosis.
  • Malignant oncocytomas have the potential risk of developing distant metastases and demand long term follow-up after therapy.
  • CASE REPORT: A 58-year old man presented with a recurrent mass in the left parotid gland with a prior diagnosis of monomorphic adenoma in the same localization which had been treated by tumor excision in July 2002.
  • CONCLUSION: For an accurate approach in the management of patients, oncocytic adenocarcinoma should be considered in the differential diagnosis of lesions of the parotid gland, most of which are benign.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Adenoma, Oxyphilic / therapy. Parotid Neoplasms / pathology. Parotid Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16974117.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


34. Heikkilä A, Siironen P, Hagström J, Heiskanen I, Sankila R, Louhimo J, Haglund C, Arola J: Follicular thyroid neoplasm: clinicopathologic features suggesting malignancy. APMIS; 2010 Nov;118(11):846-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Follicular thyroid neoplasm: clinicopathologic features suggesting malignancy.
  • Thyroid follicular neoplasms are the most common tumors of the thyroid.
  • The criterion for their malignancy is evidence of capsular or vascular invasion, which makes preoperative diagnosis difficult.
  • The poorly differentiated thyroid carcinoma entity was introduced by World Health Organization in its 2004 classification with an incidence still poorly known.
  • We found 356 follicular neoplasms treated between 1990 and 2006.
  • Among these tumor patients, adenomas were more common in women than in men (3.6:1), but carcinomas differed little with respect to gender (1.2:1).
  • All follicular carcinomas (n=39), atypical adenomas (n=6), and oxyphilic adenomas (n=15) were included in the study, as well as 30 consecutive conventional follicular adenomas.
  • Five tumors were reclassified as poorly differentiated follicular thyroid carcinomas, representing 13% of carcinomas in this unselected material.
  • High PI was also a marker of worse prognosis in malignant tumors.
  • Oxyphilic tumor cells were more frequent in carcinomas than in adenomas; however, among carcinomas, they were non-prognostic.
  • Probability for malignancy is thus greater in a male patient with a large oxyphilic follicular neoplasm.
  • The PI requires evaluation in all follicular thyroid carcinomas to identify poorly differentiated tumors with worse prognosis.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Adenoma, Oxyphilic / pathology. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. Journal Compilation © 2010 APMIS.
  • (PMID = 20955457.001).
  • [ISSN] 1600-0463
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / CCND1 protein, human; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; 136601-57-5 / Cyclin D1; EC 6.3.2.19 / MIB1 ligase, human; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  •  go-up   go-down


35. Gatto A, Falvo L, Sebastiani S, Roncolini G, Pinna G: Triple synchronous tumours of the urinary system with different histologies: a case report. Chir Ital; 2009 May-Jun;61(3):381-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present the case report of a male patient with a diagnosis of synchronous kidney, bladder and prostate tumours with different histologies: renal oncocytoma, urothelial carcinoma of the bladder, and adenocarcinoma of the prostate.
  • One such marker recently identified is the prostate-specific membrane antigen (PSMA), present with high expression in carcinoma of the prostate and in the vascular endothelium of solid tumours; only overexpression of PSMA is to be regarded as diagnostic, inasmuch as this antigen is normally expressed in the renal tubular epithelium.
  • [MeSH-minor] Adenocarcinoma / pathology. Adenoma, Oxyphilic / pathology. Aged. Carcinoma / pathology. Humans. Male. Risk Factors. Smoking / adverse effects. Treatment Outcome


36. Maiuri F, Gangemi M, Giamundo A, Mariniello G, Colella A, Vergara P, Del Basso De Caro ML: Intracranial extension of salivary gland tumors. Clin Neuropathol; 2010 Jan-Feb;29(1):9-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The primary tumors were an adenocarcinoma and a malignant oncocytoma of the parotid gland and an adenoid cystic carcinoma of the submandibular gland.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Brain Neoplasms / pathology. Carcinoma, Adenoid Cystic / pathology. Salivary Gland Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20040327.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


37. Maruya S, Shirasaki T, Nagaki T, Kakehata S, Kurotaki H, Mizukami H, Shinkawa H: Differential expression of topoisomerase IIalpha protein in salivary gland carcinomas: histogenetic and prognostic implications. BMC Cancer; 2009;9:72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of topoisomerase IIalpha protein in salivary gland carcinomas: histogenetic and prognostic implications.
  • BACKGROUND: Salivary gland carcinomas are relatively uncommon heterogeneous malignancies characterized by locoregional invasion and distant metastasis.
  • Topoisomerase IIalpha (topoIIalpha), located at chromosome 17q21-22, is considered a major mediator of cell proliferation and DNA replication.
  • METHODS: The protein expression of topoIIalpha was evaluated immunohistochemically in formalin-fixed, paraffin-embedded tissue from 54 salivary gland carcinomas and 20 benign tumors (10 pleomorphic adenomas and 10 Warthin's tumors).
  • The primary salivary gland carcinoma specimens consisted of 17 adenoid cystic carcinomas, 7 adenocarcinomas not otherwise specified, 7 mucoepidermoid carcinomas, 6 salivary duct carcinomas, 3 acinic cell carcinomas, 3 carcinomas ex pleomorphic adenomas, 3 epithelial-myoepithelial carcinomas, 2 carcinosarcomas, 2 lymphoepithelial carcinomas, 2 myoepithelial carcinomas, 1 oncocytic carcinoma, and 1 squamous cell carcinoma.
  • RESULTS: Of the 54 primary salivary gland carcinomas, 38 (70%) showed positive expression (> or = 10%) of topoIIalpha protein, and 16 carcinomas (30%) and all benign tumors were negative (p < 0.001).
  • Expression of topoIIalpha was more frequently observed in salivary duct carcinoma, carcinoma ex pleomorphic adenoma, adenocarcinoma, and adenoid cystic carcinoma, solid type, and it was associated with advanced stage and shortened survival.
  • Furthermore, it may provide useful prognostic information and suggests the potential efficacy of topoIIalpha-targeting therapy in patients with salivary gland carcinoma.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Adenoid Cystic / enzymology. Carcinoma, Adenoid Cystic / pathology. Child. Female. Humans. Immunohistochemistry. Male. Middle Aged. Prognosis. Survival Rate. Young Adult

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Head Neck. 2000 Aug;22(5):489-97 [10897109.001]
  • [Cites] Head Neck. 2008 May;30(5):680-3 [17972317.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):1061-7 [11948114.001]
  • [Cites] Clin Cancer Res. 2002 May;8(5):1107-16 [12006526.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Jun;3(6):430-40 [12042765.001]
  • [Cites] Lancet Oncol. 2002 Apr;3(4):235-43 [12067686.001]
  • [Cites] ORL J Otorhinolaryngol Relat Spec. 2003 Jan-Feb;65(1):26-32 [12624503.001]
  • [Cites] Am J Clin Pathol. 2003 May;119(5):715-22 [12760291.001]
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):4682-8 [14581337.001]
  • [Cites] Int J Oncol. 2004 Jan;24(1):201-9 [14654958.001]
  • [Cites] Anticancer Res. 2003 Sep-Oct;23(5A):3965-70 [14666704.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):944-6 [14871971.001]
  • [Cites] J Otolaryngol. 2003 Oct;32(5):328-31 [14974865.001]
  • [Cites] Mod Pathol. 2004 Jun;17(6):637-45 [15044918.001]
  • [Cites] Arch Otolaryngol. 1984 Mar;110(3):172-6 [6322732.001]
  • [Cites] Cancer. 1984 Sep 15;54(6):1062-9 [6088017.001]
  • [Cites] Oncology (Williston Park). 1998 May;12(5):671-80; discussion 683 [9597678.001]
  • [Cites] Pathol Res Pract. 2005;200(11-12):791-9 [15792122.001]
  • [Cites] Breast Cancer Res. 2005;7(3):R374-84 [15987433.001]
  • [Cites] J Clin Oncol. 2006 Jun 10;24(17):2673-8 [16763282.001]
  • [Cites] Cancer Treat Rev. 2007 Feb;33(1):64-77 [17113234.001]
  • [Cites] Oral Oncol. 2007 Sep;43(8):735-41 [17113340.001]
  • [Cites] Head Neck. 2007 Nov;29(11):1002-9 [17427971.001]
  • [Cites] Hum Pathol. 2001 Jun;32(6):596-604 [11431714.001]
  • (PMID = 19250538.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / DNA-Binding Proteins; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  • [Other-IDs] NLM/ PMC2654461
  •  go-up   go-down


38. Gerard SK, Dam HQ: Stunning with 131I diagnostic whole-body imaging of patients with thyroid cancer. Radiology; 2005 Mar;234(3):972-3; author reply 973-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adenocarcinoma, Follicular / radionuclide imaging. Adenocarcinoma, Follicular / radiotherapy. Adenocarcinoma, Follicular / surgery. Adenoma, Oxyphilic / radionuclide imaging. Adenoma, Oxyphilic / radiotherapy. Adenoma, Oxyphilic / surgery. Carcinoma, Papillary / radionuclide imaging. Carcinoma, Papillary / radiotherapy. Carcinoma, Papillary / surgery. Carcinoma, Papillary, Follicular / radionuclide imaging. Carcinoma, Papillary, Follicular / radiotherapy. Carcinoma, Papillary, Follicular / surgery. Dose-Response Relationship, Radiation. Humans. Neoplasm, Residual / radionuclide imaging. Neoplasm, Residual / radiotherapy. Radiotherapy, Adjuvant. Thyroidectomy. Treatment Outcome

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Radiology. 2004 Aug;232(2):527-33 [15286323.001]
  • (PMID = 15734947.001).
  • [ISSN] 0033-8419
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes
  •  go-up   go-down


39. Meer S, Altini M: CK7+/CK20- immunoexpression profile is typical of salivary gland neoplasia. Histopathology; 2007 Jul;51(1):26-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tumours included pleomorphic adenoma (n = 24), myoepithelioma (n = 9), papillary cystadenoma (n = 3), oncocytoma (n = 2), adenoid cystic carcinoma (n = 22), mucoepidermoid carcinoma (n = 21), polymorphous low-grade adenocarcinoma (n = 21), carcinoma ex-pleomorphic adenoma (n = 11), acinic cell carcinoma (n = 17), epimyoepithelial carcinoma (n = 7), oncocytic carcinoma (n = 3), hyalinizing clear cell carcinoma (n = 1), papillary cystadenocarcinoma (n = 1), salivary duct carcinoma (n = 3), adenocarcinoma (not otherwise specified) (n = 4) and squamous carcinoma (n = 4).
  • Squamous carcinoma showed negative CK7/20 immunoexpression.
  • CONCLUSIONS: Although the CK7/20 immunoprofile is not useful in distinguishing the various types of salivary gland neoplasms or between benign and malignant salivary gland tumours, it may facilitate differentiation of primary salivary gland neoplasia from metastatic tumours and squamous carcinoma, and the diagnosis of metastatic salivary gland tumours.
  • [MeSH-minor] Adenoma, Pleomorphic / diagnosis. Adenoma, Pleomorphic / metabolism. Adenoma, Pleomorphic / pathology. Carcinoma, Acinar Cell / diagnosis. Carcinoma, Acinar Cell / metabolism. Carcinoma, Acinar Cell / pathology. Carcinoma, Adenoid Cystic / diagnosis. Carcinoma, Adenoid Cystic / metabolism. Carcinoma, Adenoid Cystic / pathology. Carcinoma, Mucoepidermoid / diagnosis. Carcinoma, Mucoepidermoid / metabolism. Carcinoma, Mucoepidermoid / pathology. Diagnosis, Differential. Gene Expression Regulation, Neoplastic. Humans. Salivary Glands / metabolism. Salivary Glands / pathology

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17593078.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Keratin-20; 0 / Keratin-7
  •  go-up   go-down


40. Teunissen JJ, Kwekkeboom DJ, Krenning EP: Staging and treatment of differentiated thyroid carcinoma with radiolabeled somatostatin analogs. Trends Endocrinol Metab; 2006 Jan-Feb;17(1):19-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Staging and treatment of differentiated thyroid carcinoma with radiolabeled somatostatin analogs.
  • In patients with progressive metastatic (or recurrent) differentiated thyroid carcinoma that either do not take up radioiodine or are unresponsive to continued radioiodine therapy, staging is difficult and treatment options are few.
  • [MeSH-major] Adenocarcinoma, Follicular / radiotherapy. Adenoma, Oxyphilic / radiotherapy. Octreotide / therapeutic use. Radiopharmaceuticals / therapeutic use. Thyroid Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. THYROGLOBULIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16311041.001).
  • [ISSN] 1043-2760
  • [Journal-full-title] Trends in endocrinology and metabolism: TEM
  • [ISO-abbreviation] Trends Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Indium Radioisotopes; 0 / Radiopharmaceuticals; 0 / Yttrium Radioisotopes; 9010-34-8 / Thyroglobulin; RWM8CCW8GP / Octreotide
  • [Number-of-references] 52
  •  go-up   go-down


41. Jones TD, Eble JN, Cheng L: Application of molecular diagnostic techniques to renal epithelial neoplasms. Clin Lab Med; 2005 Jun;25(2):279-303
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The ultimate goal of research on the molecular pathology of renal neoplasms is a complete understanding of the genetics of these tumors, which will, in turn, aid in making the correct diagnosis, accurately assessing prognosis, and selecting appropriate and targeted therapeutic options.
  • [MeSH-major] Carcinoma, Renal Cell / genetics. Kidney Neoplasms / genetics
  • [MeSH-minor] Adenocarcinoma, Clear Cell / diagnosis. Adenocarcinoma, Clear Cell / genetics. Adenocarcinoma, Clear Cell / pathology. Adenoma, Oxyphilic / diagnosis. Adenoma, Oxyphilic / genetics. Adenoma, Oxyphilic / pathology. Basic Helix-Loop-Helix Leucine Zipper Transcription Factors. Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / genetics. Carcinoma, Papillary / pathology. DNA-Binding Proteins / genetics. Gene Dosage. Humans. Loss of Heterozygosity. Transcription Factors / genetics

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15848737.001).
  • [ISSN] 0272-2712
  • [Journal-full-title] Clinics in laboratory medicine
  • [ISO-abbreviation] Clin. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; 0 / DNA-Binding Proteins; 0 / TFE3 protein, human; 0 / Transcription Factors
  • [Number-of-references] 207
  •  go-up   go-down


42. Di Cristofaro J, Silvy M, Lanteaume A, Marcy M, Carayon P, De Micco C: Expression of tpo mRNA in thyroid tumors: quantitative PCR analysis and correlation with alterations of ret, Braf , ras and pax8 genes. Endocr Relat Cancer; 2006 Jun;13(2):485-95
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, little is known about the fate of TPO in thyroid carcinoma.
  • We performed a qualitative PCR (Q-PCR) analysis to measure the expression of variants of tpo mRNA in 13 normal tissue samples, 30 benign tumors (BT), 21 follicular carcinomas (FC), 20 classical papillary carcinomas (PCc), 12 follicular variants of papillary carcinomas (PCfv) and nine oncocytic carcinomas (OC).
  • Results of Q-PCR were closely correlated with those of ICC (P < 0.0001; R = 0.59) and showed that overall tpo expression was lower in all carcinomas than in normal and BT (P < 0.05).
  • The ratio tpo2 or tpo3 to tpo1 was inversed in follicular tumors.
  • These results confirmed the decrease of TPO expression in 97% of thyroid carcinomas regardless of histological type and the overexpression of shorter splice variants in follicular tumors.
  • [MeSH-major] Carcinoma / enzymology. Gene Expression Regulation, Neoplastic. Genes, Neoplasm / genetics. Iodide Peroxidase / genetics. Thyroid Neoplasms / enzymology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16728576.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / PAX8 protein, human; 0 / Paired Box Transcription Factors; 0 / RNA, Messenger; EC 1.11.1.8 / Iodide Peroxidase; EC 2.7.10.1 / Proto-Oncogene Proteins c-ret; EC 2.7.10.1 / RET protein, human; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  •  go-up   go-down


43. Brocks BA, Peeters ME, Kimpfler S: Oncocytoma in the mandibular salivary gland of a cat. J Feline Med Surg; 2008 Apr;10(2):188-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncocytoma in the mandibular salivary gland of a cat.
  • Initial investigations suggested a malignant salivary gland tumour, and the mass was removed by extracapsular resection of the mandibular gland.
  • Histopathology showed an oncocytoma within the salivary gland.
  • An oncocytoma is a neoplastic transformation of oncocytes.
  • Physiological proliferation occurs next to oncocytosis, oncocytoma, and oncocytic carcinoma.
  • This is the first report of an oncocytoma in a feline mandibular salivary gland, and the first report of long-term survival after surgical removal.
  • [MeSH-major] Adenoma, Oxyphilic / veterinary. Cat Diseases / diagnosis. Salivary Gland Neoplasms / veterinary

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18160323.001).
  • [ISSN] 1098-612X
  • [Journal-full-title] Journal of feline medicine and surgery
  • [ISO-abbreviation] J. Feline Med. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


44. Sav A, Scheithauer BW, Mazzola CA, Ketterling SR, Thompson SJ, Reilly MH: Oncocytic choroid plexus carcinoma: case report. Clin Neuropathol; 2010 Jan-Feb;29(1):14-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncocytic choroid plexus carcinoma: case report.
  • Herein, we report an unusual choroid plexus carcinoma with extensive oncocytic transformation.
  • Microsections revealed a WHO Grade III choroid plexus carcinoma with extensive oncocyti c transformation.
  • A minor portion of the moderately to poorly differentiated tumor exhibited classical microscopic features of choroid plexus carcinoma, including marked nuclear atypia, brisk mitotic activity (78/10 HPF), a high MIB-1 labeling index (44%) and zones of necrosis.
  • In contrast, the large, eosinophilic, cytologically malignant but granular-appearing oncocytes comprising the majority of the lesion showed scant (1/10 HPF) mitotic activity and only a low MIB-1 labeling index (5%).
  • A subsequent recurrence at 1 year consisted entirely of non-oncocytic tumor.
  • Choroid plexus carcinoma with oncocytic transformation has not been previously reported.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Brain / pathology. Carcinoma / pathology. Choroid Plexus Neoplasms / pathology
  • [MeSH-minor] Family. Female. Humans. Infant. Magnetic Resonance Imaging. Oxyphil Cells / metabolism. Oxyphil Cells / pathology. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Choroid Plexus Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20040328.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


45. Choi YJ, Yun JS, Kim DH: Clinical and ultrasound features of cytology diagnosed follicular neoplasm. Endocr J; 2009;56(3):383-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and ultrasound features of cytology diagnosed follicular neoplasm.
  • The purpose of this study was to identify clinical and ultrasound (US) features of malignancy in patients using cytological results of follicular neoplasm (FN) in the thyroid.
  • Patient histopathology, age, sex, tumor size, and US characteristics and the color flow pattern of the lesions were analyzed and compared between benign and carcinomas.
  • Twenty five (21.9%) of the 114 FN were found to be follicular carcinomas (FC); 15 minimally invasive FC, 4 widely invasive FC, and 6 FVPTC.
  • Benign included 78 FA, 8 atypical FA, and 3 Hurthle cell adenomas.
  • Color Doppler flow pattern of FN with other clinicopathological factors should be carefully considered when predicting the malignant potential of FN.
  • [MeSH-major] Adenocarcinoma, Follicular / ultrasonography. Thyroid Neoplasms / ultrasonography
  • [MeSH-minor] Adenoma, Oxyphilic / pathology. Adult. Aged. Female. Humans. Male. Middle Aged. Thyroid Gland / pathology. Thyroid Gland / ultrasonography. Ultrasonography, Doppler, Color

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19164864.001).
  • [ISSN] 1348-4540
  • [Journal-full-title] Endocrine journal
  • [ISO-abbreviation] Endocr. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


46. Adhikari P, Pradhananga RB, Sinha BK, Pradhan B, Thapa N: Oncocytoma of maxillary sinus--a rare presentation. Nepal Med Coll J; 2006 Dec;8(4):292-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncocytoma of maxillary sinus--a rare presentation.
  • A case of Oncocytoma of maxillary sinus in a 73 years old female is reported along with a brief review of literature.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Maxillary Sinus Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Aged. Female. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17357654.001).
  • [Journal-full-title] Nepal Medical College journal : NMCJ
  • [ISO-abbreviation] Nepal Med Coll J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Nepal
  •  go-up   go-down


47. Deandrea M, Ragazzoni F, Motta M, Torchio B, Mormile A, Garino F, Magliona G, Gamarra E, Ramunni MJ, Garberoglio R, Limone PP: Diagnostic value of a cytomorphological subclassification of follicular patterned thyroid lesions: a study of 927 consecutive cases with histological correlation. Thyroid; 2010 Oct;20(10):1077-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic value of a cytomorphological subclassification of follicular patterned thyroid lesions: a study of 927 consecutive cases with histological correlation.
  • To date, however, among lesions showing a follicular pattern, FNAC is still unable to differentiate between benign and malignant ones.
  • The aim of our study was to evaluate whether a subclassification of follicular cytologic specimens, based on cytoarchitectural patterns, could differentiate categories with a different risk of malignancy, thus improving the clinical management of patients harboring follicular nodules.
  • All the cytologic specimens were divided into five categories (Thy 1: inadequate material, Thy 2: benign, Thy 3: indeterminate, Thy 4: suspicious for malignancy, Thy 5: malignant).
  • Thy3 specimens were further divided into three subcategories (Thy 3a, or "follicular lesions of indeterminate significance": scant colloid, microfollicular pattern, or small clusters of thyrocytes with round nuclei usually without, but sometimes with, minimal cellular pleomorphism; Thy 3b, or "follicular neoplasm": absence of colloid, small clusters, or microfollicles of medium-large sized cell populations arranged in cohesive groups with nuclear overlapping, crowding, and pleomorphisms; and Thy 3c or "Hurthle-cell neoplasm": scant colloid, sheets or clusters of oxyphilic cells).
  • RESULTS: Thy 1 specimens (51 cases on the whole) proved to be malignant in 5.88% (3 cases), Thy 2 specimens (319) in 3.45% (11 cases), Thy 4 specimens (91) in 84.62% (77 cases), and Thy 5 specimens (172) in 98.84% (170 cases).
  • Thy 3 specimens (294 cases) proved to be malignant in 17.35% as a whole, but when divided into the three subcategories, the percentage of malignant cases was significantly different between the Thy 3a group (4.95%) and the Thy 3b and Thy 3c groups (25.0% and 22.77% respectively).
  • CONCLUSIONS: This study supports the National Cancer Institute consensus showing a different risk of malignancy for "follicular lesions of undetermined significance” compared with "follicular neoplasms" and "Hurthle cells neoplasms," which are more suspect for malignancy.
  • [MeSH-major] Adenocarcinoma, Follicular / diagnosis. Thyroid Gland / pathology. Thyroid Nodule / diagnosis
  • [MeSH-minor] Adenoma, Oxyphilic / diagnosis. Adenoma, Oxyphilic / pathology. Biopsy, Fine-Needle / methods. Humans. Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20883171.001).
  • [ISSN] 1557-9077
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Etit D, Tan A, Bayol U, Altinel D, Cumurcu S, Cukurova I: Oncocytic carcinoma ex pleomorphic adenoma. Head Neck Pathol; 2010 Mar;4(1):49-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncocytic carcinoma ex pleomorphic adenoma.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Adenoma, Pleomorphic / pathology. Neoplasms, Multiple Primary / pathology. Parotid Gland / pathology. Parotid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 2001 Jun;32(6):596-604 [11431714.001]
  • [Cites] Head Neck. 2001 Sep;23(9):705-12 [11505478.001]
  • [Cites] Ann Diagn Pathol. 2004 Aug;8(4):224-6 [15290674.001]
  • [Cites] Am J Surg. 1975 Oct;130(4):460-2 [1166937.001]
  • [Cites] Cancer. 1976 Sep;38(3):1306-17 [953970.001]
  • [Cites] Cancer. 1977 Feb;39(2):388-96 [189890.001]
  • [Cites] Acta Cytol. 1994 Jan-Feb;38(1):93-7 [8291365.001]
  • [Cites] Arch Otolaryngol. 1984 Mar;110(3):172-6 [6322732.001]
  • [Cites] J Pathol. 1985 May;146(1):51-8 [4009321.001]
  • [Cites] J Laryngol Otol. 1986 Jan;100(1):105-14 [3944499.001]
  • [Cites] Head Neck Surg. 1986 Jan-Feb;8(3):177-84 [3744850.001]
  • [Cites] Semin Surg Oncol. 1987;3(4):240-4 [3432840.001]
  • [Cites] Cancer. 1993 Sep 1;72(5):1503-12 [7688652.001]
  • [Cites] Cancer. 1977 May;39(5):2209-30 [192443.001]
  • (PMID = 20237989.001).
  • [ISSN] 1936-0568
  • [Journal-full-title] Head and neck pathology
  • [ISO-abbreviation] Head Neck Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2825533
  •  go-up   go-down


49. Troncone G, Volante M, Iaccarino A, Zeppa P, Cozzolino I, Malapelle U, Palmieri EA, Conzo G, Papotti M, Palombini L: Cyclin D1 and D3 overexpression predicts malignant behavior in thyroid fine-needle aspirates suspicious for Hurthle cell neoplasms. Cancer; 2009 Dec 25;117(6):522-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclin D1 and D3 overexpression predicts malignant behavior in thyroid fine-needle aspirates suspicious for Hurthle cell neoplasms.
  • BACKGROUND: Thyroid fine-needle aspiration (FNA) samples that feature a follicular-patterned, monotonous Hurthle (oncocytic) cell population cannot be diagnosed reliably.
  • The authors of this report recently identified cyclin D3 overexpression on histologic sections of Hurthle cell carcinoma.
  • METHODS: Fifty-one FNA samples that were suspicious for Hurtle cell neoplasia and that had histologic follow-up (19 malignant cases) were examined.
  • Cyclin D3 expression levels were evaluated in cell block preparations and were compared with levels of the closely related cyclin D1 protein.
  • Cyclin D1 and cyclin D3 were highly specific (100% for both) and fairly accurate (75% and 92%, respectively) in distinguishing between benign and malignant oncocytic lesions; the positive predictive value (PPV) for each was 100%.
  • CONCLUSIONS: Cyclin D3 increased the suspicion of malignancy in indeterminate oncocytic lesions; its diagnostic performance depended on the cutoff point used and was enhanced further when combined with cyclin D1.
  • [MeSH-major] Adenoma, Oxyphilic / diagnosis. Cyclin D1 / metabolism. Cyclin D3 / metabolism. Thyroid Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 American Cancer Society.
  • (PMID = 19787802.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin D3; 136601-57-5 / Cyclin D1
  •  go-up   go-down


50. Ghofrani M, Sosa JA, Ocal IT, Angeletti C: Fine needle aspiration of poorly differentiated oxyphilic (Hürthle cell) thyroid carcinoma: a case report. Acta Cytol; 2006 Sep-Oct;50(5):560-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine needle aspiration of poorly differentiated oxyphilic (Hürthle cell) thyroid carcinoma: a case report.
  • BACKGROUND: Poorly differentiated oxyphilic (Hürthle cell) carcinomas are a more recently described variant of poorly differentiated thyroid carcinoma and are characterized by a prominent Hürthle cell component in a solid or trabecular arrangement.
  • Clinically, poorly differentiated oxyphilic carcinomas behave more aggressively as compared to classic Hürthle cell carcinomas, which have a predominantly follicular pattern.
  • Fine needle aspiration biopsy of the mass yielded extremely cellular smears with a dual population of medium-sized follicular cells and numerous Hürthle cells.
  • Subsequent thyroidectomy confirmed the malignant nature of this Hürthle cell-rich tumor, warranting a diagnosis of poorly differentiated oxyphilic (Hürthle cell) thyroid carcinoma.
  • CONCLUSION: Poorly differentiated oxyphilic thyroid carcinoma is an aggressive variant of Hürthle cell carcinomas and must enter the differential diagnosis when fine needle aspiration biopsy of a radiologically aggressive thyroid mass yields extremely hypercellular smears with a prominent Hürthle cell component.
  • [MeSH-major] Adenocarcinoma / diagnosis. Epithelial Cells / pathology. Lung Neoplasms / diagnosis. Thyroid Gland / pathology. Thyroid Neoplasms / diagnosis
  • [MeSH-minor] Aged. Biopsy, Fine-Needle. Diagnosis, Differential. Disease Progression. Goiter, Nodular / complications. Goiter, Nodular / drug therapy. Goiter, Nodular / radiotherapy. Humans. Iodine Radioisotopes / therapeutic use. Male. Neoplasm Invasiveness. Thyroidectomy. Thyroxine / therapeutic use

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. LEVOTHYROXINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17017447.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; Q51BO43MG4 / Thyroxine
  •  go-up   go-down


51. Troncone G, Iaccarino A, Russo M, Palmieri EA, Volante M, Papotti M, Viglietto G, Palombini L: Accumulation of p27(kip1) is associated with cyclin D3 overexpression in the oxyphilic (Hurthle cell) variant of follicular thyroid carcinoma. J Clin Pathol; 2007 Apr;60(4):377-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accumulation of p27(kip1) is associated with cyclin D3 overexpression in the oxyphilic (Hurthle cell) variant of follicular thyroid carcinoma.
  • However, the oxyphilic (Hurthle cell) variant of follicular thyroid carcinoma expresses more p27 than benign oxyphilic lesions do.
  • METHODS: Because high levels of cyclin D3 lead to p27 accumulation in cell lines and clinical samples of thyroid cancer, the immunocytochemical pattern of cyclin D3 in oxyphilic (n = 47) and non-oxyphilic (n = 70) thyroid neoplasms was investigated.
  • The expression of cyclin D3 and p27 was significantly higher in the oxyphilic variant of follicular carcinomas than in non-oxyphilic carcinomas (p<0.001).
  • In co-immunoprecipitation experiments, the level of p27-bound cyclin D3 was much higher in oxyphilic neoplasias than in normal thyroids and other thyroid tumours.
  • CONCLUSION: These results show that increased p27 expression in the oxyphilic (Hurthle cell) variant of follicular thyroid carcinoma results from cyclin D3 overexpression.
  • [MeSH-minor] Adenocarcinoma, Follicular / metabolism. Adenocarcinoma, Follicular / pathology. Adenoma / metabolism. Adenoma / pathology. Adenoma, Oxyphilic / metabolism. Adenoma, Oxyphilic / pathology. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / pathology. Cyclin D3. Humans. Immunoprecipitation. Neoplasm Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Otolaryngol Head Neck Surg. 2002 Mar;128(3):253-7 [11886339.001]
  • [Cites] Mod Pathol. 2000 Sep;13(9):1014-9 [11007042.001]
  • [Cites] J Clin Pathol. 2003 Aug;56(8):587-91 [12890807.001]
  • [Cites] Mod Pathol. 2003 Sep;16(9):886-92 [13679452.001]
  • [Cites] Oncogene. 2003 Oct 23;22(48):7576-86 [14576819.001]
  • [Cites] J Histochem Cytochem. 1982 Nov;30(11):1114-22 [6183312.001]
  • [Cites] Mod Pathol. 1998 Feb;11(2):169-74 [9504687.001]
  • [Cites] J Pathol. 1998 Jun;185(2):159-66 [9713342.001]
  • [Cites] Mod Pathol. 1998 Aug;11(8):735-9 [9720501.001]
  • [Cites] Hum Pathol. 1998 Nov;29(11):1304-9 [9824112.001]
  • [Cites] Am J Pathol. 1999 Feb;154(2):313-23 [10027389.001]
  • [Cites] Am J Surg Pathol. 1999 Jun;23(6):678-85 [10366150.001]
  • [Cites] Genes Dev. 1999 Jun 15;13(12):1501-12 [10385618.001]
  • [Cites] Blood. 1999 Jul 15;94(2):765-72 [10397744.001]
  • [Cites] J Clin Invest. 1999 Oct;104(7):865-74 [10510327.001]
  • [Cites] Clin Cancer Res. 2005 Jan 1;11(1):242-8 [15671552.001]
  • [Cites] Diagn Cytopathol. 2000 Aug;23(2):77-81 [10888749.001]
  • [Cites] Clin Cancer Res. 2000 Sep;6(9):3614-20 [10999753.001]
  • [Cites] Mod Pathol. 2002 Oct;15(10):1038-43 [12379749.001]
  • (PMID = 16798934.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CCND3 protein, human; 0 / Cyclin D3; 0 / Cyclins; 0 / Neoplasm Proteins; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27
  • [Other-IDs] NLM/ PMC2001124
  •  go-up   go-down


52. Németh I, Sükösd F, Béli L, Kiss A, Pajor L, Mikó T, Iványi B: [Adult renal neoplasms in the material of the Pathology Department of the Szeged University]. Orv Hetil; 2005 Apr 3;146(14):653-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: 86.7% of all the tumours (n = 407) were malignant.
  • Among the malignant tumours, the frequency of renal cell carcinomas was 91.1% (n = 371).
  • 88.4% of the renal cell carcinomas (n = 328) were of conventional type, 5.6% (n = 21) were papillary and 4% (n = 15) were chromophobe.
  • The authors observed 3 Bellini duct, 1 mucinous tubular and 3 non-classifiable carcinomas, with a combined incidence of 1.8%.
  • 84.5% of the conventional carcinomas were clear cell (n = 277), 8.8% were eosinophilic granular (n = 29), 3.9% were multilocular cystic (n = 13) and 2.7% were sarcomatoid carcinomas (n = 9).
  • The median age of the patients with conventional carcinoma was 60 (median, range: 25-84), in the papillary group it was 62 (43-78), and in the chromophobe group was 59 (17-77).
  • The median age of patients affected by transitional cell carcinoma was 64 (range: 45-81).
  • In 13 oncocytoma cases, the tumours were initially diagnosed as malignant.
  • CONCLUSIONS: Adult malignant renal tumours affect mainly patients around the age of 60.
  • The commonest diagnosis was clear cell carcinoma of conventional type.
  • The incidence of clear cell carcinoma was 5% higher than that reported in the literature (84.5% vs 70-80%) whereas that of papillary carcinoma was 5% lower (5% vs 10-15%).
  • In comparison with the literature data, oncocytomas were relatively common (8% instead of 3%), and not rarely, it was difficult to distinguish them from renal cell carcinomas.
  • [MeSH-major] Carcinoma / epidemiology. Carcinoma / pathology. Kidney Neoplasms / epidemiology. Kidney Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Clear Cell / epidemiology. Adenocarcinoma, Clear Cell / pathology. Adenoma, Chromophobe / epidemiology. Adenoma, Chromophobe / pathology. Adenoma, Oxyphilic / epidemiology. Adenoma, Oxyphilic / pathology. Adult. Aged. Angiomyolipoma / epidemiology. Angiomyolipoma / pathology. Carcinoma, Papillary / epidemiology. Carcinoma, Papillary / pathology. Carcinoma, Renal Cell / epidemiology. Carcinoma, Renal Cell / pathology. Carcinoma, Transitional Cell / epidemiology. Carcinoma, Transitional Cell / pathology. Female. Humans. Hungary / epidemiology. Male. Middle Aged. Nephrectomy

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15889540.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


53. Sorrenti S, Trimboli P, Catania A, Ulisse S, De Antoni E, D'Armiento M: Comparison of malignancy rate in thyroid nodules with cytology of indeterminate follicular or indeterminate Hürthle cell neoplasm. Thyroid; 2009 Apr;19(4):355-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of malignancy rate in thyroid nodules with cytology of indeterminate follicular or indeterminate Hürthle cell neoplasm.
  • BACKGROUND: Thyroid nodules that are read on cytology as follicular or Hürthle cell neoplasms (FN and HN, respectively) and indeterminate for malignancy require surgery to differentiate benign from malignant nodules.
  • METHODS: We analyzed 463 nodules with an indeterminate cytological diagnosis of FN and 140 nodules with an indeterminate cytological diagnosis of HN.
  • The histopathological diagnosis after thyroidectomy was the method for establishing the diagnosis and type of malignancy.
  • Extrathyroidal invasion in the grouped HN and FN patients who had papillary thyroid carcinoma (PTC) was more common in females than in males (62% vs. 25 %, p < 0.05).
  • The rate of Hürthle cell thyroid cancer was significantly higher in HN than in FN (5.0% vs. 0.7%, p < 0.01) and the rate of the oncocytic variant of PTC was also significantly greater in HN compared to FN nodules (23.1% vs. 1.7%, p < 0.05).
  • The rate of follicular thyroid carcinoma was almost identical in patients with HN and FN (19.2% vs. 18.8 %).
  • Hürthle cell thyroid cancer and the oncocytic variant of PTC is more common in nodules with an HN indeterminate for malignancy cytology reading than in nodules with a FN indeterminate for malignancy cytology reading.
  • Since Hürthle cell thyroid cancer and the oncocytic variant of PTC are more aggressive than other thyroid cancers, it is likely that patients with an HN indeterminate for malignancy cytology will, as a group, have more aggressive thyroid cancers than those with an FN indeterminate for malignancy cytology.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Adenoma, Oxyphilic / pathology. Thyroid Neoplasms / pathology. Thyroid Nodule / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19355826.001).
  • [ISSN] 1557-9077
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Bell D, Luna MA: Warthin adenocarcinoma: analysis of 2 cases of a distinct salivary neoplasm. Ann Diagn Pathol; 2009 Jun;13(3):201-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Warthin adenocarcinoma: analysis of 2 cases of a distinct salivary neoplasm.
  • Carcinomas arising in or from the epithelial component of preexisting parotid Warthin tumors (WTs) are rare; the other histologic types of carcinoma found to arise from WTs are adenocarcinoma not otherwise specified, undifferentiated, mucoepidermoid, squamous cell, and oncocytic.
  • We have designated this neoplasm "Warthin adenocarcinoma" (WA).
  • Anderson Cancer Center for cases of malignant WT and salivary adenocarcinoma not otherwise specified diagnosed from January 1, 1985, through December 31, 2006, and evaluated patients' medical records and pathologic material.
  • Histologically, the tumors were composed of bilayered duct-like structures: The inner layer was formed by a single row of columnar oxyphilic cells expressing CK7, CK14, CK18, and AMA.
  • A residual WT with transition to carcinoma was identified in both cases.
  • Warthin adenocarcinoma is a unique salivary gland carcinoma representing the malignant epithelial counterpart of WT.
  • [MeSH-major] Adenocarcinoma / pathology. Adenolymphoma / pathology. Salivary Gland Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19433301.001).
  • [ISSN] 1532-8198
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Andreadis D, Epivatianos A, Mireas G, Nomikos A, Poulopoulos A, Yiotakis J, Barbatis C: Immunohistochemical detection of E-cadherin in certain types of salivary gland tumours. J Laryngol Otol; 2006 Apr;120(4):298-304
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIAL AND METHODS: Archival formalin-fixed, paraffin-embedded sections of 54 benign and 56 malignant tumours and 24 samples of normal and inflamed salivary gland tissue were studied immunohistochemically using an Envision/horseraddish peroxidase (HRP) technique.
  • RESULTS: In normal and inflamed salivary gland samples, E-cadherin was expressed at the membrane of acinar, myoepithelial and ductal cells located at cell-cell contact points.
  • Neoplastic epithelium in Warthin's tumours and in myoepithelial and oncocytic adenomas was strongly positive.
  • Furthermore, a weak to moderate loss of expression which was related to tissue tumour subtype was seen in malignant tumours such as: adenoid cystic carcinomas; polymorphous low-grade adenocarcinomas; acinic cell carcinomas; and mucoepidermoid low-grade, epithelial-myoepithelial, lymphoepithelial and squamous low-grade carcinomas.
  • Moderate to extreme loss or alternative cytoplasmic non-functional expression were observed in cases of salivary ductal carcinoma, carcinosarcoma, myoepithelial carcinoma, oncocytic adenocarcinoma, unspecified adenocarcinoma and squamous high-grade carcinomas.
  • [MeSH-major] Adenocarcinoma / chemistry. Biomarkers, Tumor / analysis. Cadherins / analysis. Carcinoma, Adenoid Cystic / chemistry. Carcinoma, Ductal / chemistry. Salivary Gland Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16623973.001).
  • [ISSN] 0022-2151
  • [Journal-full-title] The Journal of laryngology and otology
  • [ISO-abbreviation] J Laryngol Otol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins
  •  go-up   go-down


56. Máximo V, Botelho T, Capela J, Soares P, Lima J, Taveira A, Amaro T, Barbosa AP, Preto A, Harach HR, Williams D, Sobrinho-Simões M: Somatic and germline mutation in GRIM-19, a dual function gene involved in mitochondrial metabolism and cell death, is linked to mitochondrion-rich (Hurthle cell) tumours of the thyroid. Br J Cancer; 2005 May 23;92(10):1892-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Somatic and germline mutation in GRIM-19, a dual function gene involved in mitochondrial metabolism and cell death, is linked to mitochondrion-rich (Hurthle cell) tumours of the thyroid.
  • Oxyphil or Hurthle cell tumours of the thyroid are characterised by their consistent excessive number of mitochondria.
  • A recently discovered gene, GRIM-19 has been found to fulfil two roles within the cell: as a member of the interferon-beta and retinoic acid-induced pathway of cell death, and as part of the mitochondrial Complex I assembly.
  • In addition, a gene predisposing to thyroid tumours with cell oxyphilia (TCO) has been mapped to chromosome 19p13.2 in one family.
  • Somatic missense mutations in GRIM-19 were detected in three of 20 sporadic Hurthle cell carcinomas.
  • A germline mutation was detected in a Hurthle cell papillary carcinoma arising in a thyroid with multiple Hurthle cell nodules.
  • No mutations were detected in any of the 20 non-Hurthle cell carcinomas tested, nor in any of 96 blood donor samples.
  • In one of the sporadic Hurthle cell papillary carcinomas positive for GRIM-19 mutation, we have also detected a ret/PTC-1 rearrangement.
  • No GRIM-19 mutations were detected in any of the six cases of known familial Hurthle cell tumour tested, so that our results do not support the identification of GRIM-19 as the TCO gene.
  • The GRIM-19 mutations we have detected are the first nuclear gene mutations specific to Hurthle cell tumours to be reported to date; we propose that such mutations can be involved in the genesis of sporadic or familial Hurthle cell tumours through the dual function of GRIM-19 in mitochondrial metabolism and cell death.
  • [MeSH-major] Adenoma, Oxyphilic / genetics. Adenoma, Oxyphilic / physiopathology. Mitochondria / metabolism. Mitochondria / pathology. NADH, NADPH Oxidoreductases / genetics. Thyroid Neoplasms / genetics. Thyroid Neoplasms / physiopathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • SciCrunch. OMIM: Data: Gene Annotation .
  • SciCrunch. Clinical Genomic Database: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 1996 Jul 12;86(1):147-57 [8689682.001]
  • [Cites] J Biol Chem. 1996 May 31;271(22):13221-7 [8675499.001]
  • [Cites] Mol Cell Biol. 1998 Apr;18(4):2108-17 [9528783.001]
  • [Cites] J Pathol. 1998 May;185(1):71-8 [9713362.001]
  • [Cites] Mol Cell Biol. 1998 Nov;18(11):6493-504 [9774665.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Nov;83(11):4116-22 [9814501.001]
  • [Cites] EMBO J. 1998 Nov 16;17(22):6670-7 [9822610.001]
  • [Cites] Am J Hum Genet. 1998 Dec;63(6):1743-8 [9837827.001]
  • [Cites] J Pathol. 1998 Nov;186(3):292-9 [10211119.001]
  • [Cites] Cell. 1999 Aug 6;98(3):295-303 [10458605.001]
  • [Cites] Cancer. 1962 Sep-Oct;15:1019-27 [13904230.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Feb;85(2):878-82 [10690905.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4227-32 [10760290.001]
  • [Cites] Oncogene. 2000 Apr 13;19(16):2060-6 [10803467.001]
  • [Cites] J Interferon Cytokine Res. 2000 Jul;20(7):661-5 [10926209.001]
  • [Cites] Virchows Arch. 2000 Aug;437(2):107-15 [10993269.001]
  • [Cites] J Biol Chem. 2000 Oct 27;275(43):33416-26 [10924506.001]
  • [Cites] J Pathol. 2000 Dec;192(4):561-2 [11113879.001]
  • [Cites] Nature. 2001 Jul 5;412(6842):95-9 [11452314.001]
  • [Cites] J Biol Chem. 2001 Oct 19;276(42):38345-8 [11522775.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Jan;87(1):364-9 [11788677.001]
  • [Cites] Oncogene. 2002 Mar 27;21(13):2000-8 [11960372.001]
  • [Cites] Am J Pathol. 2002 May;160(5):1857-65 [12000737.001]
  • [Cites] Nature. 2002 Jun 27;417(6892):949-54 [12068308.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Oct;87(10):4715-21 [12364463.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Feb;88(2):938-41 [12574236.001]
  • [Cites] EMBO J. 2003 Mar 17;22(6):1325-35 [12628925.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1454-7 [12670889.001]
  • [Cites] J Natl Cancer Inst. 2003 Apr 16;95(8):625-7 [12697856.001]
  • [Cites] Mol Endocrinol. 2003 Jun;17(6):1155-66 [12637586.001]
  • [Cites] Oncogene. 2003 Jul 17;22(29):4578-80 [12881714.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9342-7 [12867595.001]
  • [Cites] J Pathol. 2004 Feb;202(2):247-51 [14743508.001]
  • [Cites] Mol Cell Biol. 2004 Oct;24(19):8447-56 [15367666.001]
  • [Cites] Ultrastruct Pathol. 1985;8(2-3):131-42 [4060255.001]
  • [Cites] Ultrastruct Pathol. 1985;8(4):269-90 [4082297.001]
  • [Cites] Cell. 1990 Feb 23;60(4):557-63 [2406025.001]
  • [Cites] Cytogenet Cell Genet. 1994;66(4):253-9 [7909283.001]
  • [Cites] Science. 1994 Jun 3;264(5164):1415-21 [8197455.001]
  • [Cites] Biochim Biophys Acta. 1995 May 24;1271(1):241-8 [7599215.001]
  • [Cites] Science. 1996 May 3;272(5262):719-22 [8614832.001]
  • [CommentIn] Br J Cancer. 2005 May 23;92(10):1817-8 [15900303.001]
  • (PMID = 15841082.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / Protein Subunits; EC 1.6.- / NADH, NADPH Oxidoreductases; EC 1.6.5.- / GRIM19 protein, human; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  • [Other-IDs] NLM/ PMC2361763
  •  go-up   go-down


57. Kajiwara H, Kumaki N, Hirabayashi K, Miyazawa M, Nakamura N, Hirasawa T, Muramatsu T, Mikami M, Yasuda M, Osamura RY: A case of oncocytic carcinoma of the endometrium. Arch Gynecol Obstet; 2009 May;279(5):733-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of oncocytic carcinoma of the endometrium.
  • We report an unusual case of endometrial adenocarcinoma in a 80-year-old woman who underwent mastectomy for breast cancer at 68 years of age.
  • Components of the carcinoma were focally observed in situ.
  • Immunostaining revealed endometrial oncocytic carcinoma.
  • Distinguishing between primary uterine neoplasm and carcinoma caused by metastasis of breast cancer appears important.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Neoplasms, Second Primary / pathology

  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18795309.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


58. Quinn TR, Duncan LM, Zembowicz A, Faquin WC: Cutaneous metastases of follicular thyroid carcinoma: a report of four cases and a review of the literature. Am J Dermatopathol; 2005 Aug;27(4):306-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous metastases of follicular thyroid carcinoma: a report of four cases and a review of the literature.
  • Cutaneous metastasis of follicular carcinoma of the thyroid is very rare, and when it occurs, can exhibit a variety of histologic appearances.
  • The cases consisted of 4 patients, 3 men and 1 woman, aged 52 to 75 years, with cutaneous metastasis of follicular thyroid carcinoma.
  • The tumors include a conventional follicular carcinoma, a follicular carcinoma with anaplastic transformation following initial metastasis, the first reported cutaneous metastases of a follicular carcinoma with oncocytic features (Hürthle cell carcinoma), and a follicular carcinoma with a prominent insular carcinoma component.
  • Three metastases retained the morphologic and immunocytochemical features of the primary thyroid tumors.
  • However, in one case there was high-grade transformation to anaplastic carcinoma following treatment of a sacral metastasis with accompanying loss of the characteristic immunophenotype of follicular thyroid carcinoma.
  • Awareness of the varied morphologies of metastatic follicular thyroid carcinoma to the skin may prompt immunohistochemical analysis and the request for a complete clinical history, ultimately preventing misdiagnosis.
  • [MeSH-major] Adenocarcinoma, Follicular / secondary. Skin Neoplasms / secondary. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16121050.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


59. Lee JS, Choi JH, Oh YH: Oncocytic carcinoma arising in the submandibular gland with disseminated bone metastases. South Med J; 2009 Jun;102(6):659-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncocytic carcinoma arising in the submandibular gland with disseminated bone metastases.
  • Oncocytic carcinoma of the head and neck is a very rare neoplasm.
  • Only 11 cases of oncocytic carcinoma of the submandibular gland have been reported, and no cases have shown distant bone metastasis.
  • The submandibular gland and bone marrow biopsies were consistent with oncocytic carcinoma.
  • Our case is the first report of oncocytic carcinoma of the submandibular gland with disseminated bone metastases.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Bone Neoplasms / secondary. Submandibular Gland Neoplasms / pathology
  • [MeSH-minor] Aged. Fatal Outcome. Humans. Male. Neoplasm Metastasis / pathology. Oxyphil Cells / pathology. Submandibular Gland / pathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19434038.001).
  • [ISSN] 1541-8243
  • [Journal-full-title] Southern medical journal
  • [ISO-abbreviation] South. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Chamnanrabiabkij E, Welch A, Jayapaul MK, Perros P: Detection of Hurthle cell carcinoma using sestamibi. Thyroid; 2008 May;18(5):575-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of Hurthle cell carcinoma using sestamibi.
  • [MeSH-major] Adenoma, Oxyphilic / radionuclide imaging. Radiopharmaceuticals. Technetium Tc 99m Sestamibi. Thyroid Neoplasms / radionuclide imaging

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18044993.001).
  • [ISSN] 1050-7256
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 971Z4W1S09 / Technetium Tc 99m Sestamibi
  •  go-up   go-down


61. Huber GF, Dziegielewski P, Matthews TW, Warshawski SJ, Kmet LM, Faris P, Khalil M, Dort JC: Intraoperative frozen-section analysis for thyroid nodules: a step toward clarity or confusion? Arch Otolaryngol Head Neck Surg; 2007 Sep;133(9):874-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In case of malignant FNAC findings, the FS result did not influence treatment decisions; in case of a malignant FS result on the background of a benign, indeterminate, or nondiagnostic FNAC finding, the FS result influenced treatment decisions in 88% of cases.
  • CONCLUSIONS: Intraoperative FS did not give additional information in cases where a malignant neoplasm was predicted by the FNAC finding.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Adenocarcinoma, Papillary / pathology. Adenoma, Oxyphilic / pathology. Biopsy, Fine-Needle. Frozen Sections. Thyroid Neoplasms / pathology. Thyroid Nodule / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cohort Studies. Decision Support Techniques. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Predictive Value of Tests. Retrospective Studies. Thyroid Diseases / pathology. Thyroid Diseases / surgery. Thyroid Gland / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17875853.001).
  • [ISSN] 0886-4470
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Motta MP, Athanazio DA, Motta A, Studart E, Athanazio PR: Parietal cell (oncocytic) adenocarcinoma of the stomach in a female patient: superficial spreading and extensive nodal involvement. Int J Surg Pathol; 2008 Oct;16(4):447-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parietal cell (oncocytic) adenocarcinoma of the stomach in a female patient: superficial spreading and extensive nodal involvement.
  • A case of parietal cell (oncocytic) adenocarcinoma in a 62-year-old woman is reported.
  • In the present case, the unusual finding of parietal cell (oncocytic) adenocarcinoma and extensive nodal metastasis in a woman is reported.
  • [MeSH-major] Adenocarcinoma / pathology. Lymphatic Metastasis / pathology. Parietal Cells, Gastric / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18387987.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Wang KL, Weinrach DM, Luan C, Han M, Lin F, Teh BT, Yang XJ: Renal papillary adenoma--a putative precursor of papillary renal cell carcinoma. Hum Pathol; 2007 Feb;38(2):239-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal papillary adenoma--a putative precursor of papillary renal cell carcinoma.
  • The precursor lesions of renal cell carcinoma (RCC) are unknown.
  • Immunohistochemistry was carried out with antibodies specific for alpha-methyl-coenzyme A racemase (AMACR) and glutathione S-transferase alpha (clear-cell RCC marker).
  • Seven papillary adenomas (18%) occurred in the setting of acquired polycystic kidney disease (APKD), 6 in clear-cell RCCs, 3 in chromophobe RCCs, 2 in end-stage kidney disease, 1 in oncocytoma, 1 in angiomyolipoma, and 1 in renal schwannoma.
  • Furthermore, papillary adenomas were more commonly found in kidneys removed for PRCC (25%, 18/71) than in kidneys harboring clear-cell RCC (1.9%, 6/318).
  • [MeSH-major] Carcinoma, Papillary / pathology. Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Clear Cell / enzymology. Adenocarcinoma, Clear Cell / pathology. Adenoma. Adenoma, Oxyphilic / enzymology. Adenoma, Oxyphilic / pathology. Adult. Aged. Aged, 80 and over. Angiomyolipoma / enzymology. Angiomyolipoma / pathology. Disease Progression. Female. Glutathione Transferase / analysis. Humans. Immunohistochemistry. Isoenzymes / analysis. Kidney / enzymology. Kidney / pathology. Kidney Failure, Chronic / enzymology. Kidney Failure, Chronic / pathology. Male. Middle Aged. Models, Biological. Polycystic Kidney Diseases / enzymology. Polycystic Kidney Diseases / pathology. Racemases and Epimerases / analysis

  • Genetic Alliance. consumer health - Papillary renal cell carcinoma.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17056094.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Isoenzymes; EC 2.5.1.18 / Glutathione Transferase; EC 2.5.1.18 / glutathione S-transferase alpha; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


64. Cheung C, Vesey D, Cotterill A, Douglas M, Gobe G, Nicol D, Johnson D: Altered messenger RNA and protein expressions for insulin-like growth factor family members in clear cell and papillary renal cell carcinomas. Int J Urol; 2005 Jan;12(1):17-28
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Altered messenger RNA and protein expressions for insulin-like growth factor family members in clear cell and papillary renal cell carcinomas.
  • BACKGROUND: The purpose of the present paper was to describe the pattern of expression of insulin-like growth factor (IGF-I) and its regulatory binding proteins (IGFBP) in renal cell carcinoma (RCC).
  • METHODS: The expressions of mRNA and protein for various IGF members were assessed in 24 paired normal and malignant human renal tissues (16 clear cell and 8 papillary RCC) using semiquantitative reverse transcription-polymerase chain reaction and immunohistochemistry.
  • Paired tissue samples were also obtained from six patients with oncocytoma in order to compare the specificity of changes in IGF/IGFBP expression between tumors derived from proximal (RCC) and distal (oncocytoma) tubular epithelium.
  • RESULTS: Clear cell RCC were characterized by significant increases in the mRNA expression of IGF-I, IGFBP-3 and IGFBP-6 while papillary RCC exhibited down-regulated expression of IGF-I, IGFBP-4 and IGFBP-5.
  • Semiquantitative assessment of immunohistochemical staining demonstrated significant increases in epithelial associated IGF-I and IGFBP-3 in clear cell RCC, increased IGFBP-5 protein in papillary RCC and no significant changes in IGF/IGFBP protein expression in oncocytoma.
  • This altered expression is differentially regulated according to the histologic subtype of RCC, and suggests that the IGF/IGFBP axis may play an important role in determining the malignant phenotype of RCC.
  • [MeSH-major] Adenocarcinoma, Clear Cell / metabolism. Carcinoma, Papillary / metabolism. Carcinoma, Renal Cell / metabolism. Insulin-Like Growth Factor I / metabolism. Kidney Neoplasms / metabolism. RNA, Messenger / metabolism
  • [MeSH-minor] Adenoma, Oxyphilic / genetics. Adenoma, Oxyphilic / metabolism. Down-Regulation. Female. Humans. Immunohistochemistry. Insulin-Like Growth Factor Binding Proteins / genetics. Insulin-Like Growth Factor Binding Proteins / metabolism. Male. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15661050.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Insulin-Like Growth Factor Binding Proteins; 0 / RNA, Messenger; 67763-96-6 / Insulin-Like Growth Factor I
  •  go-up   go-down


65. Li C, Mazhari M, Perera M, Rana DN: Hurthle cell carcinoma with myxoid stroma - a rare entity and a diagnosis pitfall. Cytopathology; 2010 Apr;21(2):120-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hurthle cell carcinoma with myxoid stroma - a rare entity and a diagnosis pitfall.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20059506.001).
  • [ISSN] 1365-2303
  • [Journal-full-title] Cytopathology : official journal of the British Society for Clinical Cytology
  • [ISO-abbreviation] Cytopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; Thyroid cancer, Hurthle cell
  •  go-up   go-down


66. Favia G, Iacobone M, Zanella S, Ciarleglio FA: Management of invasive and advanced thyroid cancer. Minerva Endocrinol; 2009 Mar;34(1):37-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adenocarcinoma, Follicular / pathology. Adenocarcinoma, Follicular / secondary. Adenocarcinoma, Follicular / therapy. Adenoma, Oxyphilic / surgery. Carcinoma / radiotherapy. Carcinoma / secondary. Carcinoma / surgery. Carcinoma, Medullary / surgery. Carcinoma, Papillary / pathology. Carcinoma, Papillary / secondary. Carcinoma, Papillary / therapy. Child. Combined Modality Therapy. Female. Humans. Iodine Radioisotopes / therapeutic use. Larynx / pathology. Lymphatic Metastasis. Neck Muscles / pathology. Neoplasm Invasiveness. Neoplasm Staging. Palliative Care. Prognosis. Recurrent Laryngeal Nerve / pathology. Thyroidectomy. Trachea / pathology

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19209127.001).
  • [ISSN] 0391-1977
  • [Journal-full-title] Minerva endocrinologica
  • [ISO-abbreviation] Minerva Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Iodine Radioisotopes
  • [Number-of-references] 174
  •  go-up   go-down


67. Kunju LP, Wojno K, Wolf JS Jr, Cheng L, Shah RB: Papillary renal cell carcinoma with oncocytic cells and nonoverlapping low grade nuclei: expanding the morphologic spectrum with emphasis on clinicopathologic, immunohistochemical and molecular features. Hum Pathol; 2008 Jan;39(1):96-101
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Papillary renal cell carcinoma with oncocytic cells and nonoverlapping low grade nuclei: expanding the morphologic spectrum with emphasis on clinicopathologic, immunohistochemical and molecular features.
  • Papillary renal cell carcinoma (PRCC), a morphologically and genetically distinct subtype of RCC, is morphologically separated into 2 subtypes, type 1 and 2, for prognostic purposes.
  • Type 1 PRCC (single layer of small cells, scant pale cytoplasm) is more common and has a favorable prognosis compared with type 2 (pseudostratified high-grade nuclei, abundant eosinophilic/oncocytic cytoplasm).
  • All tumors demonstrated predominant papillary architecture, lined by cells with oncocytic cytoplasm, and nonoverlapping low Fuhrman grade nuclei (1 or 2).
  • These results suggest that these tumors are distinct from type 1 (owing to oncocytic cells) and type 2 (owing to low-grade nonstratified nuclei, low stage, and good outcome).
  • Awareness of this favorable spectrum of PRCC is important to avoid its potential misinterpretation as an aggressive type 2 PRCC (owing to oncocytic cells) or rarely as an oncocytoma (owing to oncocytic cells and low-grade nuclei).
  • Morphologic spectrum of these PRCCs emphasizes that the future prognostic model of PRCC may need to be based primarily on the nuclear characteristics, irrespective of the cytoplasmic features.
  • [MeSH-major] Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Cell Nucleus / pathology. Chromosome Aberrations. Cytoplasm / pathology. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Middle Aged. Trisomy


68. Young RH: From Krukenberg to today: the ever present problems posed by metastatic tumors in the ovary. Part II. Adv Anat Pathol; 2007 May;14(3):149-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The first tumor discussed is gastric carcinoma of intestinal-type whose ovarian manifestations have been the subject of a recent paper which emphasized its differences from the Krukenberg tumor.
  • Coverage of intestinal adenocarcinoma emphasizes the landmark 1987 paper of RH Lash and WR Hart.
  • The section on pancreatic neoplasms reemphasizes the problems caused by metastatic ductal carcinoma, considered primarily in Part I, and discusses less common issues such as spread of neuroendocrine and acinar cell carcinomas.
  • The limited information on spread of tumors of the gallbladder and extrahepatic bile ducts is then reviewed before more detailed consideration of hepatic neoplasms, prompted by recent contributions on hepatocellular carcinoma and intrahepatic cholangiocarcinoma, the latter based on significant experience with this problem in Thailand.
  • The section on appendiceal neoplasms highlights ovarian spread of diverse tumors ranging from typical intestinal-type adenocarcinoma to signet-ring cell carcinomas with various patterns which in the ovary may prompt diagnoses such as a goblet cell (mucinous) carcinoid tumor, but whose ovarian features place them in the category of a Krukenberg tumor.
  • The diverse problems in differential diagnosis of carcinoid tumor (provoked by nested, acinar, and other patterns, including folliclelike spaces) are then reviewed.
  • The section on lung tumors largely reflects information in a recent paper that small cell carcinoma and adenocarcinoma are the lung cancers that spread to the ovary most commonly.
  • The extremely broad differential diagnosis posed by metastatic malignant melanoma ranging from that of an oxyphilic tumor, to a small cell tumor, to a follicle-forming neoplasm, is then considered.
  • The sections on renal cell carcinoma and other urinary tract neoplasms emphasize the differential diagnosis of metastatic clear cell carcinoma and primary clear cell carcinoma, an issue usually resolvable by an awareness of the various features of the ovarian variant, rarely or never seen in the renal variant.
  • The sections on ovarian spread of uterine carcinomas emphasize the problems owing to cervical adenocarcinomas, which have a greater tendency to involve the ovaries than squamous cell carcinomas and can simulate primary mucinous or endometrioid cancers.
  • The final neoplasms considered are malignant mesothelioma and the desmoplastic small round cell tumor.
  • The microscopic features of malignant mesothelioma are so different from those of primary ovarian carcinoma in most instances that the diagnosis should be readily established on routine microscopic evaluation.
  • The differential diagnosis of the desmoplastic small round cell tumor is more complex because of the greater overlap with the many other small cell malignant tumors that may involve the ovaries primarily or secondarily.
  • However, as pointed out in brief concluding remarks, despite the aid of that modality, as in surgical pathology overall, careful consideration of the clinical background, distribution of disease, gross characteristics and spectrum of routine microscopic findings, will lead to the correct diagnosis in the majority of cases and at the very least lead to formulation of a considered differential diagnosis such that use of special techniques may be judicious and those results placed in context of the time-honored clinical and pathologic features.
  • [MeSH-major] Carcinoma / secondary. Krukenberg Tumor / secondary. Ovarian Neoplasms / secondary
  • [MeSH-minor] Diagnosis, Differential. Female. History, 19th Century. History, 20th Century. Humans

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17452813.001).
  • [ISSN] 1072-4109
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Historical Article; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 67
  •  go-up   go-down


69. Perlman EJ: Pediatric Renal Cell Carcinoma. Surg Pathol Clin; 2010 Sep 1;3(3):641-651
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric Renal Cell Carcinoma.
  • Renal cell carcinomas are rare in children, and they show significant differences in their histology and pathogenesis when compared to those common in adults.
  • The most common subtypes seen preferentially in children are the translocation-associated tumors, papillary renal cell carcinoma, renal medullary carcinoma, and oncocytic renal cell carcinoma following neuroblastoma.
  • The histological diagnosis of renal cell carcinoma is made difficult by the considerable heterogeneity within and overlap between each of the above subtypes and by similarities to other pediatric renal neoplasms.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21057600.001).
  • [ISSN] 1875-9157
  • [Journal-full-title] Surgical pathology clinics
  • [ISO-abbreviation] Surg Pathol Clin
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA098543; None / None / / U10 CA098543-08; United States / NCI NIH HHS / CA / U10 CA098543-08
  • [Publication-type] JOURNAL ARTICLE
  • [Publication-country] United States
  •  go-up   go-down


70. Balcerzak W, Bednarz W, Domosławski P, Olewiński R, Kolesińska J, Kaminski Z, Dziarkowska K, Wieczorek P: [Preliminary approach towards construction of peptide libraries as potential tools for diagnosis of malignant thyroid tumors]. Endokrynol Pol; 2006 Jul-Aug;57(4):307-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Preliminary approach towards construction of peptide libraries as potential tools for diagnosis of malignant thyroid tumors].
  • The treatment improvement could be achieved by early diagnosis.
  • MATERIAL AND METHODS: The material from 6 patients with thyroid cancer (4 with papillary cancer, 1 with follicular cancer and 1 with oxyphilic tumor) were analyzed.
  • It was performed with use of lipophylic peptide libraries by direct comparison of staining of specimens prepared from normal and malignant tissue.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Adenoma, Oxyphilic / pathology. Biomarkers, Tumor / analysis. Carcinoma, Papillary, Follicular / pathology. Peptide Library. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17006829.001).
  • [ISSN] 0423-104X
  • [Journal-full-title] Endokrynologia Polska
  • [ISO-abbreviation] Endokrynol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Galectin 3; 0 / Peptide Library; EC 1.11.1.8 / Iodide Peroxidase
  •  go-up   go-down


71. Elliott DD, Pitman MB, Bloom L, Faquin WC: Fine-needle aspiration biopsy of Hurthle cell lesions of the thyroid gland: A cytomorphologic study of 139 cases with statistical analysis. Cancer; 2006 Apr 25;108(2):102-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine-needle aspiration biopsy of Hurthle cell lesions of the thyroid gland: A cytomorphologic study of 139 cases with statistical analysis.
  • BACKGROUND: Lesions of the thyroid gland composed of Hurthle cells encompass pathologic entities ranging from hyperplastic nodules with Hurthle cell metaplasia to Hurthle cell carcinomas.
  • Many cytologic features of Hurthle cell lesions that distinguish neoplastic Hurthle cell lesions requiring surgery from those that are benign and nonneoplastic have been described, but with variable usefulness.
  • A morphologic study was made of 139 Hurthle cell lesions of the thyroid gland and statistical analysis applied to identify a set of cytomorphologic features that distinguish benign Hurthle cell lesions (BHCL) from Hurthle cell neoplasms (HCN).
  • METHODS: Fine-needle aspiration biopsies (FNABs) of thyroid nodules with a predominant Hurthle cell component and corresponding histologic followup were included in the study.
  • Cases were divided into BHCL and HCN groups on the basis of the histologic diagnosis.
  • All cases were reviewed to assess the following 14 cytologic features: overall cellularity, cytoarchitecture, percentage of Hurthle cells, percentage of single cells, percentage of follicular cells observed as naked Hurthle cell nuclei, background colloid, chronic inflammation, cystic change, transgressing blood vessels (TBV), intracytoplasmic lumina, presence of multinucleated Hurthle cells, nuclear to cytoplasmic ratio, nuclear pleomorphism/atypia, and nucleolar prominence.
  • Six of the 14 cytologic features evaluated were shown by univariate analysis to be statistically significant in predicting HCN: nonmacrofollicular architecture (P < 0.001), absence of background colloid (P < 0.001), absence of chronic inflammation (P < 0.001), presence of TBV (P < 0.001), > 90% Hurthle cells (P < 0.001), and >10% single Hurthle cells (P = 0.014).
  • CONCLUSIONS: In the current study of 139 FNAB specimens of thyroid Hurthle cell nodules, 14 cytologic features were examined and 6 were found to be statistically significant in identifying HCN.
  • [MeSH-major] Adenoma / pathology. Adenoma, Oxyphilic / pathology. Oxyphil Cells / pathology. Thyroid Gland / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy, Fine-Needle. Cell Nucleus / pathology. Colloids / analysis. Cytoplasm / pathology. Data Interpretation, Statistical. Diagnosis, Differential. Female. Humans. Logistic Models. Male. Metaplasia / pathology. Middle Aged

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • (PMID = 16453320.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Colloids
  •  go-up   go-down


72. Ferru A, Denis S, Guilhot J, Gibelin H, Tourani JM, Kraimps JL, Larsen CJ, Karayan-Tapon L: Expression of TAp73 and DeltaNp73 isoform transcripts in thyroid tumours. Eur J Surg Oncol; 2006 Mar;32(2):228-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: By comparison to normal thyroid tissue surrounding the tumours, we observed significant downregulation of TP73 transcripts in adenomas and in differentiated carcinomas.
  • Correlations were found in normal tissue specimens between the expression of TAp73 and DeltaNp73 transcripts and that of p53, p14ARF p16INK4a, but these correlations were lost in carcinomas (PTC or FTC).
  • [MeSH-major] Adenocarcinoma, Follicular / chemistry. Adenoma, Oxyphilic / chemistry. Carcinoma, Papillary / chemistry. DNA-Binding Proteins / analysis. Nuclear Proteins / analysis. Thyroid Neoplasms / chemistry. Tumor Suppressor Proteins / analysis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16290057.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / Protein Isoforms; 0 / RNA, Messenger; 0 / Tumor Suppressor Protein p14ARF; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


73. Albores-Saavedra J, Hernandez M, Sanchez-Sosa S, Simpson K, Angeles A, Henson DE: Histologic variants of papillary and follicular carcinomas associated with anaplastic spindle and giant cell carcinomas of the thyroid: an analysis of rhabdoid and thyroglobulin inclusions. Am J Surg Pathol; 2007 May;31(5):729-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histologic variants of papillary and follicular carcinomas associated with anaplastic spindle and giant cell carcinomas of the thyroid: an analysis of rhabdoid and thyroglobulin inclusions.
  • We describe the histologic variants of papillary and follicular carcinomas associated with 109 spindle and giant cell carcinomas (SGCC) of the thyroid and determine the incidence of rhabdoid and thyroglobulin inclusions in these tumors.
  • In addition, we searched for rhabdoid and thyroglobulin inclusions in 120 papillary carcinomas (PC) (all 15 variants included), 23 differentiated follicular carcinomas (DFC), (6 with insular pattern), 6 poorly differentiated follicular carcinomas (PDFC) and 34 follicular adenomas (FA).
  • The following differentiated thyroid carcinomas coexisted with SGCC: 51 (46.8%) PC, (34 conventional type, 14 tall cell variant and 3 follicular variant), 6 (5.5%) DFC, 1 follicular carcinoma with insular pattern (0.9%), and 3 oncocytic carcinomas (2.8%).
  • Thyroglobulin inclusions were found in 10 FA (29%), 8 (17%) follicular variants of PC and in 7 (30.4%) DFC.
  • The finding that only 1 (0.9%) SGCC was associated with follicular carcinoma with insular pattern contradicts the opinion that this tumor occupies an intermediate position between differentiated and anaplastic carcinomas.
  • Rhabdoid features are markers of PDFC and SGCC while thyroglobulin inclusions are markers of FA and differentiated thyroid carcinomas with follicular phenotype.
  • [MeSH-major] Carcinoma / pathology. Carcinoma, Giant Cell / pathology. Carcinoma, Papillary, Follicular / pathology. Inclusion Bodies / pathology. Rhabdoid Tumor / pathology. Thyroglobulin / metabolism. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. THYROGLOBULIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17460457.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9010-34-8 / Thyroglobulin
  •  go-up   go-down


74. Dewil B, Van Damme B, Vander Poorten V, Delaere P, Debruyne F: Completion thyroidectomy after the unexpected diagnosis of thyroid cancer. B-ENT; 2005;1(2):67-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Completion thyroidectomy after the unexpected diagnosis of thyroid cancer.
  • In our department, routine management includes completion thyroidectomy once the histopathological report concludes that there is carcinoma, except in cases of papillary carcinoma measuring less than 1 cm.
  • We reviewed the records of 29 patients--25 women and 4 men-- who all underwent completion thyroidectomy because of an unexpected diagnosis of DTC.
  • Because of the rather low re-operation rate, we prefer to perform a completion thyroidectomy to remove potential occult malignancy and to allow for postoperative 131I-treatment in all patients with a diagnosis of malignancy in their thyroid lobectomy specimen, with the exception of papillary carcinoma < 1 cm.
  • [MeSH-major] Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / surgery. Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / surgery. Thyroidectomy / methods
  • [MeSH-minor] Adenocarcinoma, Follicular / diagnosis. Adenocarcinoma, Follicular / surgery. Adenoma, Oxyphilic / diagnosis. Adenoma, Oxyphilic / surgery. Adolescent. Adult. Aged. Biopsy, Fine-Needle. Female. Humans. Male. Middle Aged. Neoplasm, Residual. Retrospective Studies. Thyroid Gland / pathology. Thyroid Gland / radionuclide imaging. Thyroid Gland / ultrasonography. Treatment Outcome

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16044737.001).
  • [ISSN] 1781-782X
  • [Journal-full-title] B-ENT
  • [ISO-abbreviation] B-ENT
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


75. Sahin M, Allard BL, Yates M, Powell JG, Wang XL, Hay ID, Zhao Y, Goellner JR, Sebo TJ, Grebe SK, Eberhardt NL, McIver B: PPARgamma staining as a surrogate for PAX8/PPARgamma fusion oncogene expression in follicular neoplasms: clinicopathological correlation and histopathological diagnostic value. J Clin Endocrinol Metab; 2005 Jan;90(1):463-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PPARgamma staining as a surrogate for PAX8/PPARgamma fusion oncogene expression in follicular neoplasms: clinicopathological correlation and histopathological diagnostic value.
  • The PAX8/PPARgamma (PPFP) fusion-oncogene is moderately specific for follicular thyroid carcinomas (FTC).
  • It remains unknown whether this can be translated into improved diagnosis, classification, or outcome prediction.
  • We studied a cohort of well-characterized follicular adenomas (FA), FTC, and Hurthle cell carcinomas (HCC) from patients with complete clinical follow-up, to determine whether PPARgamma immunohistochemistry (as a surrogate of PAX8/PPARgamma expression) helps to distinguish FA from FTC and to assess its diagnostic accuracy as an adjunct to frozen section.
  • PPARgamma staining was associated with favorable prognostic indicators (female gender, better tumor differentiation, and lesser risk of metastases).PPARgamma staining may be helpful in the differential diagnosis of FA, FTC, and HCC, particularly when diagnostic sensitivity of histomorphology is reduced (e.g. during intraoperative frozen section).

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15483076.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA80117
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / PAX8 protein, human; 0 / PPAR gamma; 0 / Paired Box Transcription Factors; 0 / Recombinant Fusion Proteins; 0 / Trans-Activators
  •  go-up   go-down


76. Raef H, Alfadhli E, Al-Hajjaj A, Malabu UH, Al-Sobhi S, Rifai A, Al Nuaim A: High rate of persistent/recurrent disease among patients with differentiated thyroid cancer in Saudi Arabia: factors affecting nonremission. Ann Saudi Med; 2008 Jul-Aug;28(4):277-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Papillary thyroid cancer was found in 76%, the follicular variant in 14%, other variants (tall cell and sclerosing types) in 2%, Hurthle cell carcinoma in 4%, and pure follicular thyroid cancer in 4%.

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18596397.001).
  • [ISSN] 0256-4947
  • [Journal-full-title] Annals of Saudi medicine
  • [ISO-abbreviation] Ann Saudi Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


77. Choi YL, Kim MK, Suh JW, Han J, Kim JH, Yang JH, Nam SJ: Immunoexpression of HBME-1, high molecular weight cytokeratin, cytokeratin 19, thyroid transcription factor-1, and E-cadherin in thyroid carcinomas. J Korean Med Sci; 2005 Oct;20(5):853-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunoexpression of HBME-1, high molecular weight cytokeratin, cytokeratin 19, thyroid transcription factor-1, and E-cadherin in thyroid carcinomas.
  • To examine the immunohistochemical alterations associated with the histological dedifferentiation of thyroid carcinomas, we performed staining for HBME-1, high molecular weight cytokeratin (HCK), CK 19, thyroid transcription factor-1 (TTF-1) and E-cadherin (E-CD) on 125 various types of thyroid carcinomas.
  • The HBME-1 staining was strong and diffuse in follicular carcinoma (FC), papillary carcinoma (PC), and poorly differentiated carcinoma (PDC), while it was rare in undifferentiated carcinoma (UC) as well as in benign lesions.
  • Strong, diffuse staining for CK19 and HCK was predominantly found in PC, and these markers were not much found in other carcinomas.
  • TTF-1 uniformly stained the tumor cells of all cases of PC, FC and Hurthle cell carcinoma (HC) and 42% of the PDC, while there was only focal staining in one case of the UC.
  • These results suggest that HBME-1 may be a marker for well-differentiated carcinomas while CK19 and HCK are phenotypic markers for papillary carcinoma.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 1999 Oct;30(10):1166-71 [10534163.001]
  • [Cites] Mod Pathol. 2000 May;13(5):570-6 [10824930.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2000 Mar;8(1):42-8 [10937048.001]
  • [Cites] Endocr Pathol. 2003 Spring;14(1):55-60 [12746563.001]
  • [Cites] Histopathology. 2003 Jun;42(6):580-7 [12786894.001]
  • [Cites] J Otolaryngol. 2003 Oct;32(5):319-22 [14974863.001]
  • [Cites] Cancer Res. 1993 Oct 15;53(20):4987-93 [8402689.001]
  • [Cites] Endocrinology. 1995 Jul;136(7):3113-9 [7789339.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Jul;80(7):2168-72 [7608273.001]
  • [Cites] Endocrinology. 1995 Oct;136(10):4672-80 [7664688.001]
  • [Cites] Cell Growth Differ. 1996 Feb;7(2):251-61 [8822209.001]
  • [Cites] Int J Cancer. 1997 Jan 6;70(1):32-8 [8985087.001]
  • [Cites] Cancer Res. 1997 Jun 15;57(12):2501-7 [9192832.001]
  • [Cites] Mod Pathol. 1997 Jul;10(7):668-74 [9237176.001]
  • [Cites] Diagn Cytopathol. 1998 Feb;18(2):93-7 [9484636.001]
  • [Cites] Cancer Res. 1998 May 15;58(10):2063-6 [9605742.001]
  • [Cites] J Pathol. 1998 Jul;185(3):267-72 [9771480.001]
  • [Cites] Cancer Res. 1999 Apr 15;59(8):1811-5 [10213482.001]
  • [Cites] J Korean Med Sci. 2005 Feb;20(1):98-104 [15716612.001]
  • (PMID = 16224162.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / HBME-1 antigen; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1; 68238-35-7 / Keratins
  • [Other-IDs] NLM/ PMC2779285
  •  go-up   go-down


78. Stolnicu S, Borda A, Radulescu D, Puscasiu L, Berger N, Nogales FF: Metastasis from papillary renal cell carcinoma masquerading as primary ovarian clear cell tumor. Pathol Res Pract; 2007;203(11):819-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasis from papillary renal cell carcinoma masquerading as primary ovarian clear cell tumor.
  • Differential diagnosis included primary ovarian oxyphilic-type clear cell carcinoma and sex-cord tumor with extensive luteinization.
  • However, analysis of the patient's past history revealed that in 2003, she had undergone nephrectomy for a papillary renal cell carcinoma, and a histological comparison between the primary and the present tumor exhibited in the latter a substantially larger number of clear cells and loss of papillary architecture.
  • This is the first reported case of ovarian metastases of type II tubulopapillary carcinoma of the kidney.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Carcinoma, Renal Cell / secondary. Kidney Neoplasms / pathology. Ovarian Neoplasms / secondary
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Neprilysin / metabolism. Racemases and Epimerases / metabolism


79. Yang XY, Hu CX, Yang LZ, Zhao WC, Pan Y: [Hurthle cell thyroid tumor: an analysis of 28 cases]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2010 Nov;45(11):908-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hurthle cell thyroid tumor: an analysis of 28 cases].
  • OBJECTIVE: To explore the clinical features and the combined treatment modality of Hurthle cell thyroid tumor (HCT).
  • Postoperative pathological examination showed that 22 cases were Hurthle cell adenomas and 6 cases were Hurthle cell carcinomas, 1 of them with cervical lymph node metastasis.
  • Twenty-one patients with Hurthle cell adenomas were followed up for 6 months to 7.5 years (with a median of 45 months) and 6 patients with Hurthle cell carcinomas for 3 to 8 years (with a median of 54 months), with no recurrence and death case.
  • CONCLUSIONS: HCT is a potential malignant neoplasm.
  • There are some difficulties in the diagnosis of HCT by frozen section.
  • [MeSH-major] Adenoma, Oxyphilic / diagnosis. Adenoma, Oxyphilic / surgery. Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21215204.001).
  • [ISSN] 1673-0860
  • [Journal-full-title] Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  • [ISO-abbreviation] Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


80. Arcinas A, Yen TY, Kebebew E, Macher BA: Cell surface and secreted protein profiles of human thyroid cancer cell lines reveal distinct glycoprotein patterns. J Proteome Res; 2009 Aug;8(8):3958-68
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell surface and secreted protein profiles of human thyroid cancer cell lines reveal distinct glycoprotein patterns.
  • Cell surface proteins have been shown to be effective therapeutic targets.
  • Thus, identification of cell surface and secreted proteins has been a prime area of interest in the proteomics field.
  • Most cell surface and secreted proteins are known to be glycosylated, and therefore, a proteomics strategy targeting these proteins was applied to obtain proteomic profiles from various thyroid cancer cell lines that represent the range of thyroid cancers of follicular cell origin.
  • In this study, we oxidized the carbohydrates of secreted proteins and those on the cell surface with periodate and isolated them via covalent coupling to hydrazide resin.
  • Thyroid cancer cell lines derived from papillary thyroid cancer (TPC-1), follicular thyroid cancer (FTC-133), Hurthle cell carcinoma (XTC-1), and anaplastic thyroid cancer (ARO and DRO-1) were evaluated.
  • An average of 150 glycoproteins were identified per cell line, of which more than 57% are known cell surface or secreted glycoproteins.
  • In addition to glycoproteins that are commonly expressed by all of the cell lines, we identified others that are only expressed in the more well-differentiated thyroid cancer cell lines (follicular, Hurthle cell and papillary), or by cell lines derived from undifferentiated tumors that are uniformly fatal forms of thyroid cancer (i.e., anaplastic).

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. SODIUM M-PERIODATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):5043-51 [17075124.001]
  • [Cites] Matrix Biol. 2006 Sep;25(7):443-56 [16934444.001]
  • [Cites] Exp Oncol. 2007 Mar;29(1):54-60 [17431390.001]
  • [Cites] Mol Cancer Res. 2007 Jun;5(6):553-67 [17579117.001]
  • [Cites] J Pathol. 2007 Aug;212(4):411-9 [17573672.001]
  • [Cites] Cancer Res. 2007 Jul 15;67(14):6777-85 [17638889.001]
  • [Cites] Anal Chem. 2007 Aug 1;79(15):5826-37 [17591751.001]
  • [Cites] Cancer Sci. 2007 Nov;98(11):1666-77 [17727684.001]
  • [Cites] Dev Biol. 2007 Oct 15;310(2):291-303 [17822691.001]
  • [Cites] Biophys J. 2008 Feb 15;94(4):1326-40 [17933878.001]
  • [Cites] Br J Cancer. 2008 Feb 26;98(4):818-23 [18212751.001]
  • [Cites] Cancer Res. 2008 Mar 1;68(5):1572-80 [18316623.001]
  • [Cites] Cancer. 2008 Mar 15;112(6):1313-24 [18257091.001]
  • [Cites] Curr Opin Cell Biol. 2008 Apr;20(2):194-200 [18353626.001]
  • [Cites] Mol Cell Proteomics. 2008 May;7(5):825-44 [17913849.001]
  • [Cites] Nat Rev Immunol. 2008 Aug;8(8):577-80 [18617884.001]
  • [Cites] Jpn J Clin Oncol. 2008 Aug;38(8):528-33 [18664479.001]
  • [Cites] J Proteome Res. 2008 Sep;7(9):4079-88 [18665625.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Nov;93(11):4331-41 [18713817.001]
  • [Cites] J Biol Chem. 2008 Nov 21;283(47):32802-11 [18718903.001]
  • [Cites] Int J Gynecol Cancer. 2008 Nov-Dec;18(6):1215-33 [18217975.001]
  • [Cites] Mol Cell Proteomics. 2009 Feb;8(2):287-301 [18923192.001]
  • [Cites] Clin Cancer Res. 2005 Apr 15;11(8):2840-52 [15837731.001]
  • [Cites] Electrophoresis. 1999 Dec;20(18):3551-67 [10612281.001]
  • [Cites] Proteomics. 2002 Jun;2(6):706-12 [12112852.001]
  • [Cites] Electrophoresis. 2002 Sep;23(18):3205-16 [12298092.001]
  • [Cites] Anal Chem. 2002 Oct 15;74(20):5383-92 [12403597.001]
  • [Cites] Nat Biotechnol. 2003 Jun;21(6):660-6 [12754519.001]
  • [Cites] Oncogene. 2003 Sep 29;22(42):6524-36 [14528277.001]
  • [Cites] Rapid Commun Mass Spectrom. 2003;17(20):2310-6 [14558131.001]
  • [Cites] Annu Rev Cell Dev Biol. 2003;19:397-422 [14570575.001]
  • [Cites] Anal Chem. 2003 Sep 1;75(17):4646-58 [14632076.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Dec 15;88(24):11222-6 [1722323.001]
  • [Cites] Cancer. 1993 Sep 15;72(6):1991-6 [8364879.001]
  • [Cites] Cancer. 1994 Jun 1;73(11):2808-17 [7514955.001]
  • [Cites] Endocr Rev. 1999 Apr;20(2):207-39 [10204118.001]
  • [Cites] Nat Biotechnol. 1999 Jul;17(7):676-82 [10404161.001]
  • [Cites] Mol Cancer. 2004 Nov 17;3:31 [15548330.001]
  • [Cites] Clin Cancer Res. 2005 Mar 1;11(5):1713-21 [15755992.001]
  • [Cites] Thyroid. 2005 Sep;15(9):1011-20 [16187909.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Oct;6(10):801-11 [16314869.001]
  • [Cites] J Proteome Res. 2005 Nov-Dec;4(6):2070-80 [16335952.001]
  • [Cites] Surgery. 2005 Dec;138(6):1102-9; discussion 1109-10 [16360397.001]
  • [Cites] Mol Cell Proteomics. 2006 Feb;5(2):226-33 [16263699.001]
  • [Cites] J Pathol. 2006 Mar;208(4):453-61 [16470907.001]
  • [Cites] Exp Cell Res. 2006 Mar 10;312(5):659-67 [16256984.001]
  • [Cites] Ann Surg Oncol. 2006 Apr;13(4):453-64 [16474910.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):2918-22 [16540638.001]
  • [Cites] Histopathology. 2006 Apr;48(5):612-4 [16623792.001]
  • [Cites] Mol Cell Proteomics. 2006 May;5(5):845-57 [16467180.001]
  • [Cites] Cancer Control. 2006 Apr;13(2):99-105 [16735983.001]
  • [Cites] J Proteome Res. 2006 Jun;5(6):1493-503 [16740002.001]
  • [Cites] Cancer. 2006 Jun 15;106(12):2592-7 [16688775.001]
  • [Cites] Cell. 2006 Jun 16;125(6):1151-63 [16777604.001]
  • [Cites] J Biol Chem. 2006 Jun 30;281(26):18257-63 [16648631.001]
  • [Cites] Int J Cancer. 2006 Oct 1;119(7):1638-47 [16646078.001]
  • [Cites] Pathol Int. 2006 Sep;56(9):485-9 [16930327.001]
  • [Cites] Surg Oncol. 2006 Jul;15(1):43-55 [16950080.001]
  • [Cites] Cesk Patol. 2006 Jul;42(3):120-4 [16955558.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • (PMID = 19530676.001).
  • [ISSN] 1535-3893
  • [Journal-full-title] Journal of proteome research
  • [ISO-abbreviation] J. Proteome Res.
  • [Language] ENG
  • [Grant] United States / NIMHD NIH HHS / MD / MD000544-06; United States / NIGMS NIH HHS / GM / R25 GM048972; United States / NIMHD NIH HHS / MD / P20 MD000544; United States / NIMHD NIH HHS / MD / P20 MD000544-06; United States / NIGMS NIH HHS / GM / GM048972
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glycoproteins; 0 / Hydrazines; 0 / Membrane Proteins; 0 / Neoplasm Proteins; 0 / Peptide Fragments; 10450-60-9 / Periodic Acid; B45A1BUM4Q / metaperiodate; EC 3.5.1.52 / Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase
  • [Other-IDs] NLM/ NIHMS132564; NLM/ PMC2735218
  •  go-up   go-down


81. D'Antonio A, Caleo A, Caleo O, Addesso M, Boscaino A: Hepatocellular carcinoma metastatic to the kidney mimicking renal oncocytoma. Hepatobiliary Pancreat Dis Int; 2010 Oct;9(5):550-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatocellular carcinoma metastatic to the kidney mimicking renal oncocytoma.
  • BACKGROUND: Renal metastases of hepatocellular carcinoma (HCC) are very rare.
  • RESULTS: Histologically, the tumor was composed mainly of epithelioid cells with homogeneous acidophilic cytoplasm resembling oncocytoma or primary renal carcinoma with oncocytic features.
  • A correct diagnosis was made on the basis of positive immunostaining for hepatocyte paraffin 1.
  • Since HCC may histologically resemble primary renal tumors such as oncocytoma, pathologists must be aware of this possibility above all in patients referred for liver transplantation and treated with immunosuppressant drugs.
  • Immunohistochemistry is particularly helpful to establish a precise diagnosis in cases of doubt.
  • [MeSH-major] Carcinoma, Hepatocellular / diagnosis. Carcinoma, Hepatocellular / pathology. Kidney Neoplasms / diagnosis. Kidney Neoplasms / secondary. Liver Neoplasms / diagnosis. Liver Neoplasms / pathology
  • [MeSH-minor] Adenoma, Oxyphilic / diagnosis. Diagnosis, Differential. Fatal Outcome. Female. Humans. Liver Transplantation / pathology. Middle Aged. Neoplasm Metastasis

  • Genetic Alliance. consumer health - Oncocytoma renal.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20943467.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] Oncocytoma, renal
  •  go-up   go-down


82. Bałdys-Waligórska A, Gołkowski F, Krzentowska-Korek A, Hubalewska-Dydejczyk A: Radioiodine ablation of thyroid remnants in patients with differentiated thyroid carcinoma (DTC) following administration of rhTSH - a comparison with L-thyroxine withdrawal. Endokrynol Pol; 2010 Sep-Oct;61(5):474-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radioiodine ablation of thyroid remnants in patients with differentiated thyroid carcinoma (DTC) following administration of rhTSH - a comparison with L-thyroxine withdrawal.
  • INTRODUCTION: A group of differentiated thyroid carcinoma (DTC) patients receiving post thyroidectomy rhTSH-aided radioiodine treatment (group I) was compared with patients treated with ¹³¹I following endogenous stimulation of TSH (group II) after L-thyroxine withdrawal.
  • [MeSH-major] Adenocarcinoma, Papillary / radiotherapy. Iodine Radioisotopes / therapeutic use. Thyrotropin / therapeutic use
  • [MeSH-minor] Adenocarcinoma, Follicular. Adenoma, Oxyphilic. Female. Humans. Lymph Node Excision. Male. Middle Aged. Neoplasm Staging. Neoplasm, Residual. Postoperative Care. Thyroid Neoplasms / pathology. Thyroid Neoplasms / radiotherapy. Thyroid Neoplasms / surgery. Thyroidectomy. Thyroxine / administration & dosage

  • Hazardous Substances Data Bank. LEVOTHYROXINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21049461.001).
  • [ISSN] 0423-104X
  • [Journal-full-title] Endokrynologia Polska
  • [ISO-abbreviation] Endokrynol Pol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 9002-71-5 / Thyrotropin; Q51BO43MG4 / Thyroxine; Thyroid cancer, Hurthle cell
  •  go-up   go-down


83. Griniatsos J, Tsigris C, Kanakis M, Kaltsas G, Michail O, Dimitriou N, Argyrakopoulou G, Delladetsima I, Kyriakou V, Syriou V, Alexandraki K, Pikoulis E, Giannopoulos A, Kouraklis G, Diamanti-Kandaraki E, Felekouras E: Increased incidence of papillary thyroid cancer detection among thyroidectomies in Greece between 1991 and 2006. Anticancer Res; 2009 Dec;29(12):5163-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma, Follicular / epidemiology. Adenoma, Oxyphilic / epidemiology. Carcinoma / epidemiology. Carcinoma, Medullary / epidemiology. Carcinoma, Papillary / epidemiology. Thyroid Neoplasms / epidemiology. Thyroidectomy


84. Mazal PR, Stichenwirth M, Koller A, Blach S, Haitel A, Susani M: Expression of aquaporins and PAX-2 compared to CD10 and cytokeratin 7 in renal neoplasms: a tissue microarray study. Mod Pathol; 2005 Apr;18(4):535-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Immunohistochemistry for aquaporin-1, aquaporin-2, PAX-2, CD10, and cytokeratin 7 was performed on 102 clear cell renal cell carcinomas, 44 papillary renal cell carcinomas (among them 34 type 1 and 10 type 2), 24 chromophobe renal cell carcinomas, three collecting duct carcinomas (carcinomas of the collecting ducts of Bellini), and 29 oncocytomas.
  • Aquaporin-1 expression was found in clear cell renal cell carcinomas and papillary renal cell carcinomas of both types (78 and 73%, respectively), but not in chromophobe renal cell carcinomas, collecting duct carcinomas, and oncocytomas.
  • PAX-2 and CD10 was found in the majority of clear cell renal cell carcinomas (88 and 85%, respectively) but only in few papillary renal cell carcinomas, chromophobe renal cell carcinomas and oncocytomas.
  • Decrease or loss of aquaporin-1 and PAX-2 was shown in higher grades compared to lower grades of clear cell renal cell carcinomas (P<0.0001 and <0.0245, respectively).
  • Cytokeratin 7 was rarely seen in clear cell renal cell carcinomas, type 2 papillary renal cell carcinomas, and oncocytomas, but was found in the majority of type 1 papillary renal cell carcinomas (97.1%) and chromophobe renal cell carcinomas (88%).
  • Aquaporin-1 and PAX-2 expression was found to correlate with nuclear grading for clear cell renal cell carcinomas but not for papillary renal cell carcinomas.
  • Aquaporin-1 and PAX-2 are reliable markers for clear cell renal cell carcinomas of lower grades but not for higher grades.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / metabolism. Adenocarcinoma, Clear Cell / pathology. Adenoma, Oxyphilic / metabolism. Adenoma, Oxyphilic / pathology. Aquaporin 1. Aquaporin 2. Aquaporins / biosynthesis. Blood Group Antigens. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / pathology. Carcinoma, Renal Cell / metabolism. Carcinoma, Renal Cell / pathology. DNA-Binding Proteins / biosynthesis. Humans. Immunohistochemistry. Keratin-7. Keratins / biosynthesis. Kidney / chemistry. Kidney / pathology. Neoplasm Staging. Neprilysin / biosynthesis. PAX2 Transcription Factor. Tissue Array Analysis / methods. Transcription Factors / biosynthesis

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15502805.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AQP1 protein, human; 0 / AQP2 protein, human; 0 / Aquaporin 2; 0 / Aquaporins; 0 / Biomarkers, Tumor; 0 / Blood Group Antigens; 0 / DNA-Binding Proteins; 0 / KRT7 protein, human; 0 / Keratin-7; 0 / PAX2 Transcription Factor; 0 / PAX2 protein, human; 0 / Transcription Factors; 146410-94-8 / Aquaporin 1; 68238-35-7 / Keratins; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


85. Perepletchikov AM, Alroy J, Ucci A: Diagnostic utility of CD10, CD3 and electron microscopy of renal cortical neoplasms with oncocytic features. Pathol Res Pract; 2010 Jun 15;206(6):384-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic utility of CD10, CD3 and electron microscopy of renal cortical neoplasms with oncocytic features.
  • No currently defined imaging techniques can reliably distinguish between oncocytoma and epithelial malignant lesions with oncocytic features in the kidney; therefore, patients must undergo resection or, in certain circumstances, biopsy to definitively establish diagnosis.
  • Immunohistochemical staining for CD10 and CD3, evaluation of the staining pattern and intensity, and relevant morphologic appearance are helpful diagnostic tools in discriminating between renal cell carcinoma with oncocytic features and renal oncocytoma.
  • Electron microscopy confirms different ultrastructural components of each neoplastic cell type and correlates with immunohistochemical findings.
  • [MeSH-major] Antigens, CD3 / biosynthesis. Carcinoma, Renal Cell / ultrastructure. Kidney Neoplasms / ultrastructure. Neprilysin / biosynthesis
  • [MeSH-minor] Adenoma, Oxyphilic. Aged. Biomarkers, Tumor / analysis. Diagnosis, Differential. Humans. Immunohistochemistry. Male. Microscopy, Electron, Transmission

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published by Elsevier GmbH.
  • (PMID = 19942355.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD3; 0 / Biomarkers, Tumor; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


86. Pu RT, Yang J, Wasserman PG, Bhuiya T, Griffith KA, Michael CW: Does Hurthle cell lesion/neoplasm predict malignancy more than follicular lesion/neoplasm on thyroid fine-needle aspiration? Diagn Cytopathol; 2006 May;34(5):330-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does Hurthle cell lesion/neoplasm predict malignancy more than follicular lesion/neoplasm on thyroid fine-needle aspiration?
  • The diagnosis of an adequately sampled thyroid FNA is generally grouped into three categories: benign, malignant, and indeterminate.
  • The latter group usually includes follicular neoplasm, follicular lesion, and sometimes a more specific diagnosis such as Hurthle cell neoplasm or follicular lesion/neoplasm with Hurthle cell change.
  • Whether a FNA diagnosis of Hurthle cell lesion/neoplasm (HLN) denotes a worse clinical outcome than follicular lesion/neoplasm (FLN) remains controversial.
  • A cohort of 303 thyroid FNA cases with follow-up thyroidectomy in our institutes was identified, with the follow-up excision diagnosis compared to the FNA diagnosis in order to address this issue.
  • Of this cohort, 87 cases had an FNA diagnosis of HLN while 216 cases had a diagnosis of FLN.
  • Upon excision, the FNA diagnosis of HLN group had 14 cases of goiter/nodular hyperplasia (16%), 46 cases of adenoma (12 follicular adenoma (14%) and 34 cases of Hurthle cell adenoma (39%)), and 27 cases of carcinoma (31%, 12 papillary carcinoma and 15 Hurthle cell carcinoma).
  • The FLN group had 74 cases of goiter/nodular hyperplasia (34.3%), 8 cases of Hashimoto thyroiditis (3.7%), 73 cases of follicular adenoma (33.8%), one case of granular cell tumor, and 60 cases of carcinoma (27.8%, 46 papillary carcinoma, 12 follicular carcinoma, and 1 Hurthle cell carcinoma and 1 parathyroid carcinoma) upon excision.
  • There is no significant difference in predicting cancer between the two cytology diagnosis groups (HLN versus FLN, 31% versus 27.8%, P = 0.5771).
  • When sorting all the cases by the surgical diagnosis, while comparable for age at diagnosis, the cancer group having the higher proportion of male patients than the non-cancer group (28.7% versus 16.7%, P = 0.0259).
  • Hurthle cell carcinoma patients are typically older than patients with other cancer diagnoses (59 versus 44, P = 0.0077).
  • Our results suggest that an FNA diagnosis of HLN does not predict more malignancy than FLN.
  • Males and older patients with a HLN FNA diagnosis carry a higher risk of Hurthle cell carcinoma upon thyroidectomy.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Adenoma / pathology. Adenoma, Oxyphilic / pathology. Biopsy, Fine-Needle / methods. Oxyphil Cells / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Papillary / pathology. Adenocarcinoma, Papillary / surgery. Adolescent. Adult. Aged. Aged, 80 and over. Cohort Studies. Female. Goiter, Nodular / pathology. Goiter, Nodular / surgery. Humans. Hyperplasia / pathology. Hyperplasia / surgery. Male. Middle Aged. Prognosis. Thyroid Nodule / pathology. Thyroid Nodule / surgery. Thyroidectomy

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16604553.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. ul Haq RN, Khan BA, Chaudhry IA: Prevalence of malignancy in goitre--a review of 718 thyroidectomies. J Ayub Med Coll Abbottabad; 2009 Oct-Dec;21(4):134-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Prevalence of papillary and follicular carcinoma was 33.33% each.
  • Anaplastic carcinoma was found in 23.81% of patients followed by Hurthle cell carcinoma in 9.53% of patients.
  • Prevalence of follicular carcinoma and anaplastic carcinoma is relatively higher in our country due to high incidence of iodine deficiency goitre.
  • [MeSH-minor] Adolescent. Adult. Carcinoma, Papillary / epidemiology. Carcinoma, Papillary / pathology. Child. Female. Humans. Male. Middle Aged. Pakistan / epidemiology. Prevalence. Prospective Studies. Thyroidectomy. Young Adult

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21067046.001).
  • [ISSN] 1025-9589
  • [Journal-full-title] Journal of Ayub Medical College, Abbottabad : JAMC
  • [ISO-abbreviation] J Ayub Med Coll Abbottabad
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


88. Pusiol T, Franceschetti I, Piscioli I: Oncocytic carcinoma: review of the literature. J Oral Maxillofac Surg; 2009 Sep;67(9):2035-7; author reply 2037
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncocytic carcinoma: review of the literature.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Parotid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] J Oral Maxillofac Surg. 1999 Mar;57(3):325-8 [10077205.001]
  • (PMID = 19686946.001).
  • [ISSN] 1531-5053
  • [Journal-full-title] Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons
  • [ISO-abbreviation] J. Oral Maxillofac. Surg.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  •  go-up   go-down


89. Rubello D, Pelizzo MR, Casara D, Piotto A, Toniato A, Fig L, Gross M: Radio-guided surgery for non-131I-avid thyroid cancer. Thyroid; 2006 Nov;16(11):1105-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There were 33 papillary (one "tall" cell variant), 2 follicular, and 2 Hürthle cell cancers.
  • [MeSH-major] Carcinoma, Papillary / radionuclide imaging. Carcinoma, Papillary / surgery. Radiosurgery / methods. Thyroid Neoplasms / radionuclide imaging. Thyroid Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma, Follicular / radionuclide imaging. Adenocarcinoma, Follicular / secretion. Adenocarcinoma, Follicular / surgery. Adenoma, Oxyphilic / radionuclide imaging. Adenoma, Oxyphilic / secretion. Adenoma, Oxyphilic / surgery. Adolescent. Adult. Aged. Female. Humans. Iodine Radioisotopes. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local / radionuclide imaging. Neoplasm Recurrence, Local / surgery. Radiopharmaceuticals. Technetium Tc 99m Sestamibi. Thyroglobulin / blood

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. THYROGLOBULIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17123337.001).
  • [ISSN] 1050-7256
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 0 / Radiopharmaceuticals; 9010-34-8 / Thyroglobulin; 971Z4W1S09 / Technetium Tc 99m Sestamibi
  •  go-up   go-down


90. Spanu A, Solinas ME, Chessa F, Sanna D, Nuvoli S, Madeddu G: 131I SPECT/CT in the follow-up of differentiated thyroid carcinoma: incremental value versus planar imaging. J Nucl Med; 2009 Feb;50(2):184-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 131I SPECT/CT in the follow-up of differentiated thyroid carcinoma: incremental value versus planar imaging.
  • Planar 131I scintigraphy is routinely used to detect radioiodine-avid metastases of differentiated thyroid carcinoma (DTC).
  • [MeSH-minor] Adenocarcinoma, Follicular / radiography. Adenocarcinoma, Follicular / radionuclide imaging. Adenocarcinoma, Follicular / secondary. Adenocarcinoma, Follicular / surgery. Adenocarcinoma, Papillary / radiography. Adenocarcinoma, Papillary / radionuclide imaging. Adenocarcinoma, Papillary / secondary. Adenocarcinoma, Papillary / surgery. Adenoma, Oxyphilic / radiography. Adenoma, Oxyphilic / radionuclide imaging. Adenoma, Oxyphilic / secondary. Adenoma, Oxyphilic / surgery. Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Male. Middle Aged. Thyroidectomy. Young Adult

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Nucl Med. 2009 Aug;50(8):1386; author reply 1386 [19617337.001]
  • (PMID = 19164225.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes
  •  go-up   go-down


91. Yuen HK, Cheuk W, Cheng AC, Anh C, Chan N: Malignant oncocytoma of the lacrimal sac as an unusual cause of epiphora. Ophthal Plast Reconstr Surg; 2007 Jan-Feb;23(1):70-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant oncocytoma of the lacrimal sac as an unusual cause of epiphora.
  • Incisional biopsy revealed malignant oncocytoma of the lacrimal sac.
  • Patients with malignant oncocytoma may present with simple epiphora in absence of other signs and symptoms such as blood stained tearing or purulent rhinorrhea.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Eye Neoplasms / pathology. Lacrimal Apparatus Diseases / pathology

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • MedlinePlus Health Information. consumer health - Tears.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17237701.001).
  • [ISSN] 0740-9303
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


92. Djekidel M, Gordon M, Shah RB, Gross MD, Avram A: Renal metastasis from Hurthle cell thyroid carcinoma and its evaluation with hybrid imaging. Thyroid; 2010 Apr;20(4):429-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal metastasis from Hurthle cell thyroid carcinoma and its evaluation with hybrid imaging.
  • BACKGROUND: In general, thyroid carcinomas, when they behave aggressively, metastasize to lungs and occasionally to bone and brain.
  • Here we report, to the best of our knowledge, the first patient with Hurthle cell thyroid cancer and renal metastasis.
  • SUMMARY: The patient was a 75-year-old man who had a history of a total thyroidectomy 9 years previously for a right thyroid lobe Hurthle cell carcinoma.
  • Anatomic imaging characteristics favored a primary renal cell cancer with the additional evidence of renal vein invasion and thrombosis.
  • Histology later revealed a metastatic renal Hurthle cell cancer with positive thyroglobulin stains.
  • [MeSH-major] Adenocarcinoma, Follicular / secondary. Kidney Neoplasms / secondary. Thyroid Neoplasms / pathology

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. THYROGLOBULIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Thyroid. 2010 Nov;20(11):1321; author reply 321-2 [21062198.001]
  • (PMID = 20373987.001).
  • [ISSN] 1557-9077
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18; 9010-34-8 / Thyroglobulin
  •  go-up   go-down


93. Melck A, Bugis S, Baliski C, Irvine R, Anderson DW, Wilkins G, Zhang H, Wiseman SM: Hemithyroidectomy: the preferred initial surgical approach for management of Hurthle cell neoplasm. Am J Surg; 2006 May;191(5):593-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hemithyroidectomy: the preferred initial surgical approach for management of Hurthle cell neoplasm.
  • BACKGROUND: The objective of this study was to evaluate the cancer risk of patient clinicopathologic characteristics to determine the optimal approach for the surgical management of individuals with Hurthle cell neoplasm (HN) diagnosed by cytology.
  • The association of these characteristics with a pathologic cancer diagnosis was evaluated using Fisher's exact test and Student t test.
  • RESULTS: Of the 422 patients undergoing thyroidectomy, 27 presented with a fine-needle aspiration biopsy diagnosis of HN, and by pathologic assessment 7 HN patients (25.9%) had a cancer diagnosis.
  • Although none of the clinicopathologic characteristics evaluated were able to reliably differentiate benign from malignant tumors, large tumor size and male sex were significantly associated with a pathologic diagnosis of Hurthle cell carcinoma (P < .05).
  • CONCLUSIONS: Hemithyroidectomy represents the preferred initial surgical approach for the management of individuals presenting with nodular thyroid disease and a cytologic diagnosis of HN.
  • [MeSH-major] Adenoma, Oxyphilic / surgery. Thyroid Neoplasms / surgery. Thyroidectomy / methods
  • [MeSH-minor] Adult. Biopsy, Fine-Needle. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Male. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16647343.001).
  • [ISSN] 0002-9610
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


94. Kuroda N, Tamura M, Taguchi T, Tominaga A, Hes O, Michal M, Ohara M, Hirouchi T, Mizuno K, Hayashi Y, Shuin T, Lee GH: Sarcomatoid acquired cystic disease-associated renal cell carcinoma. Histol Histopathol; 2008 11;23(11):1327-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sarcomatoid acquired cystic disease-associated renal cell carcinoma.
  • In this article, we report a rare case of hitherto undescribed acquired cystic disease (ACD)-associated renal cell carcinoma (RCC) with sarcomatoid change.
  • Microscopically, oncocytic cuboidal cells proliferated with tubular, cribriform or papillary growth patterns, and atypical columnar cells with abundant cytoplasm proliferated with papillary configuration.
  • The cytoplasm of oncocytic and sarcomatous neoplastic cells was diffusely positive for anti-mitochondrial antibody and the ultrastructural examination detected many mitochondria in the cytoplasm of oncocytic carcinoma cells and sarcomatous neoplastic cells.
  • We thus report here a case of hitherto undescribed ACD-associated RCC intermingled with oncocytic cells, translocation type RCC-like area and sarcomatoid change.
  • [MeSH-major] Carcinoma, Renal Cell / etiology. Kidney Diseases, Cystic / complications. Kidney Failure, Chronic / etiology. Kidney Neoplasms / etiology. Sarcoma / etiology
  • [MeSH-minor] Aged. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Nephrectomy. Nucleic Acid Hybridization. Oxyphil Cells / ultrastructure. Renal Dialysis


95. Morelli L, Pusiol T, Piscioli F: [Ovarian oxyphilic Sertoli cell tumor: case report and review of the literature]. Pathologica; 2006 Jun;98(3):184-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ovarian oxyphilic Sertoli cell tumor: case report and review of the literature].
  • [Transliterated title] Tumore a cellule di Sertoli ossifile dell'ovaio: caso clinico e revisione della letteratura.
  • Ovarian oxyphilic Sertoli cell tumor is a rare neoplasm (only three cases were reported in literature).
  • Pathologist 1 made a diagnosis of endometrioid adenocarcinoma, while Pathologist 2 made the diagnosis of oxyphilic Sertoli cell tumor.
  • He sends the same slides to Pathologist 1, who confirmed his diagnosis.
  • The two different diagnosis set different managements of the lesion for the clinician, but overall they set the pathologist who requested the consultation in a difficult position.
  • [MeSH-major] Ovarian Neoplasms / pathology. Sertoli Cell Tumor / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. HEMATOXYLIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17036948.001).
  • [ISSN] 0031-2983
  • [Journal-full-title] Pathologica
  • [ISO-abbreviation] Pathologica
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Coloring Agents; 0 / Fluorescent Dyes; TDQ283MPCW / Eosine Yellowish-(YS); YKM8PY2Z55 / Hematoxylin
  • [Number-of-references] 1
  •  go-up   go-down


96. Foschini MP, Malvi D, Betts CM: Oncocytic carcinoma arising in Warthin tumour. Virchows Arch; 2005 Jan;446(1):88-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncocytic carcinoma arising in Warthin tumour.
  • [MeSH-major] Adenolymphoma / pathology. Oxyphil Cells / pathology. Parotid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virchows Arch. 2002 May;440(5):536-42 [12021929.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1988 Jan;65(1):61-6 [3422397.001]
  • [Cites] Am J Surg Pathol. 1998 Feb;22(2):221-30 [9500224.001]
  • [Cites] Histopathology. 1998 Oct;33(4):379-86 [9822930.001]
  • (PMID = 15455232.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Germany
  •  go-up   go-down


97. McHugh JB, Hoschar AP, Dvorakova M, Parwani AV, Barnes EL, Seethala RR: p63 immunohistochemistry differentiates salivary gland oncocytoma and oncocytic carcinoma from metastatic renal cell carcinoma. Head Neck Pathol; 2007 Dec;1(2):123-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p63 immunohistochemistry differentiates salivary gland oncocytoma and oncocytic carcinoma from metastatic renal cell carcinoma.
  • Metastatic renal cell carcinoma (RCC) can pose diagnostic challenges in the head and neck often resembling benign and malignant oncocytic lesions.
  • Nineteen oncocytomas, 9 cases of oncocytosis, 9 oncocytic carcinomas and 16 head and neck metastatic RCC were studied.
  • Morphologic features evaluated were cytoplasmic character (clear versus oncocytic), Fuhrman nuclear grade, mitotic rate, growth pattern, presence of lumens/blood lakes and stromal characteristics.
  • Tumors were stained with antibodies to p63, renal cell carcinoma marker (RCCm), CD10, and vimentin.
  • Eight benign oncocytic tumors (29%) had clear cell features while 6 metastatic RCC (37%) had oncocytic features.
  • Median Fuhrman nuclear grade was 2 in oncocytoma and oncocytosis and 3 both oncocytic carcinoma and metastatic RCC.
  • Mitotic rates were only significantly different between benign oncocytic tumors and metastatic RCC.
  • Seven benign oncocytic tumors (25%) and 5 oncocytic carcinomas (56%) had RCC-like vascular stroma.
  • All primary salivary gland tumors were positive for p63, predominately in basal cell-type distribution.
  • While clinical history and morphology usually are adequate, demonstration of p63 staining can definitively exclude metastatic RCC from the differential diagnosis of similar appearing tumors in salivary glands, namely oncocytoma and oncocytic carcinoma, with 100% specificity and sensitivity.
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Adenoma, Oxyphilic / diagnosis. Carcinoma, Renal Cell / diagnosis. Kidney Neoplasms / diagnosis. Membrane Proteins / metabolism. Salivary Gland Neoplasms / diagnosis. Salivary Gland Neoplasms / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Diagnosis, Differential. Humans. Predictive Value of Tests

  • Genetic Alliance. consumer health - Oncocytoma renal.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Invest Dermatol. 1999 Dec;113(6):1099-105 [10594758.001]
  • [Cites] Otolaryngol Head Neck Surg. 2002 Jun;126(6):657-62 [12087334.001]
  • [Cites] Am J Surg Pathol. 2001 Aug;25(8):1054-60 [11474290.001]
  • [Cites] Adv Anat Pathol. 2002 Sep;9(5):280-9 [12195217.001]
  • [Cites] Laryngoscope. 2002 Sep;112(9):1598-602 [12352670.001]
  • [Cites] Virchows Arch. 2002 Nov;441(5):428-36 [12447671.001]
  • [Cites] J Histochem Cytochem. 2003 Feb;51(2):133-9 [12533521.001]
  • [Cites] J Histochem Cytochem. 2003 Aug;51(8):1097-9 [12871991.001]
  • [Cites] Lab Invest. 1970 Dec;23(6):567-80 [5530737.001]
  • [Cites] Mich Med. 1971 Jul;70(16):616-8 [5571989.001]
  • [Cites] Laryngoscope. 1973 Jun;83(6):898-905 [4711327.001]
  • [Cites] Laryngoscope. 1981 Apr;91(4):517-9 [6261053.001]
  • [Cites] South Med J. 1981 Sep;74(9):1050-2 [7280750.001]
  • [Cites] Pathol Res Pract. 1986 Dec;181(6):684-92 [3562340.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1988 Jan;65(1):61-6 [3422397.001]
  • [Cites] Hum Pathol. 1988 Jul;19(7):862-7 [3402976.001]
  • [Cites] Head Neck. 1989 Mar-Apr;11(2):174-8 [2656583.001]
  • [Cites] Histopathology. 1990 May;16(5):487-93 [2361662.001]
  • [Cites] Am J Surg Pathol. 1991 Jun;15(6):514-28 [2031528.001]
  • [Cites] Pathol Annu. 1992;27 Pt 1:263-304 [1736246.001]
  • [Cites] Cancer. 1996 Dec 1;78(11):2281-7 [8940996.001]
  • [Cites] Semin Diagn Pathol. 1997 Aug;14(3):203-12 [9279976.001]
  • [Cites] J Oral Pathol Med. 1998 May;27(5):225-8 [9682986.001]
  • [Cites] Mol Cell. 1998 Sep;2(3):305-16 [9774969.001]
  • [Cites] Am J Surg Pathol. 2007 Jan;31(1):44-57 [17197918.001]
  • [Cites] Nature. 1999 Apr 22;398(6729):714-8 [10227294.001]
  • [Cites] Laryngoscope. 2005 Jun;115(6):1097-100 [15933529.001]
  • [Cites] Head Neck. 2005 Aug;27(8):696-702 [16021638.001]
  • [Cites] Otolaryngol Head Neck Surg. 2000 Mar;122(3):464 [10699832.001]
  • [Cites] Am J Clin Pathol. 2001 Dec;116(6):823-30 [11764070.001]
  • [Cites] Trends Genet. 2002 Feb;18(2):90-5 [11818141.001]
  • [Cites] Clin Cancer Res. 2002 Feb;8(2):494-501 [11839669.001]
  • [Cites] Arch Pathol Lab Med. 2002 Jun;126(6):676-85 [12033955.001]
  • [Cites] Int J Surg Pathol. 2005 Oct;13(4):329-35 [16273188.001]
  • (PMID = 20614263.001).
  • [ISSN] 1936-0568
  • [Journal-full-title] Head and neck pathology
  • [ISO-abbreviation] Head Neck Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CKAP4 protein, human; 0 / Membrane Proteins
  • [Other-IDs] NLM/ PMC2807526
  • [Keywords] NOTNLM ; Metastatic renal cell carcinoma / Oncocytic carcinoma / Oncocytoma / p63
  •  go-up   go-down


98. Tamaskar I, Choueiri TK, Sercia L, Rini B, Bukowski R, Zhou M: Differential expression of caveolin-1 in renal neoplasms. Cancer; 2007 Aug 15;110(4):776-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Caveolin-1 is a major component of membrane caveolae, which are specialized lipid raft microdomains on cell membrane that are implicated in molecular transport, cell adhesion, and signal transduction.
  • The overexpression of caveolin-1 recently was associated with a poor outcome in patients with clear-cell renal cell carcinoma (CCRCC) and was proposed as a useful diagnostic marker.
  • METHODS: A tissue microarray (TMA) was constructed from 60 normal kidneys, 22 CCRCCs, 20 papillary renal cell carcinomas (PRCCs), 16 chromophobe renal cell carcinomas (ChRCCs), and 19 oncocytomas (ONCs).
  • Thus, the current results indicated that caveolin-1 expression may have potential both as a diagnostic marker in the differential diagnosis of renal tumors and as a therapeutic target, especially for CCRCC.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / metabolism. Adenocarcinoma, Clear Cell / pathology. Adenoma, Oxyphilic / metabolism. Adenoma, Oxyphilic / pathology. Adult. Aged. Aged, 80 and over. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / pathology. Carcinoma, Renal Cell / metabolism. Carcinoma, Renal Cell / pathology. Cohort Studies. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Kidney / chemistry. Kidney / pathology. Male. Middle Aged. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17594718.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Caveolin 1
  •  go-up   go-down


99. Parameswaran R, Brooks S, Sadler GP: Molecular pathogenesis of follicular cell derived thyroid cancers. Int J Surg; 2010;8(3):186-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular pathogenesis of follicular cell derived thyroid cancers.
  • Three mitogenic signalling pathways have been described in the thyroid cell, which are influenced by various stimulatory and inhibitory hormones, growth factors and neurotransmitters.
  • Two theories have been described in thyroid cancer pathogenesis, the foetal cell carcinogenesis theory and the more common, multistep carcinogenesis theory.
  • This results in the formation of differentiated thyroid cancers like the papillary, follicular or Hurthle cell cancers.
  • Based on this theory, follicular carcinomas are generated from follicular adenomas and papillary carcinomas from precursor cells generated from thyrocytes.
  • Anaplastic carcinoma may develop from papillary or follicular carcinoma by dedifferentiation.
  • [MeSH-minor] Adenocarcinoma, Follicular / genetics. Adenocarcinoma, Follicular / physiopathology. Adenoma, Oxyphilic / genetics. Adenoma, Oxyphilic / physiopathology. Carcinoma, Papillary / genetics. Carcinoma, Papillary / physiopathology. Humans


100. Valladares Ayerbes M, Aparicio Gallego G, Díaz Prado S, Jiménez Fonseca P, García Campelo R, Antón Aparicio LM: Origin of renal cell carcinomas. Clin Transl Oncol; 2008 Nov;10(11):697-712
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Origin of renal cell carcinomas.
  • Cancer is a heritable disorder of somatic cells: environment and heredity are both important in the carcinogenic process.
  • The primal force is the "two hits" of Knudson's hypothesis, which has proved true for many tumours, including renal cell carcinoma.
  • In contrast, sporadic tumours would develop only if a mutation occurred in both alleles within the same cell, and, as each event would be expected to occur with low frequency, most tumours would develop late in life and in a unifocal manner [3, 4].
  • Each of the inherited syndromes predisposes to distinct types of renal carcinoma.
  • A surprising number of genetic syndromes predispose to the development of renal cell carcinoma, and genes associated with five of these syndromes have been already identified: VHL, MET, FH, BHD and HRPT2.
  • Few cancers have as many different types of genetic predisposition as renal cancer, although to date only a small proportion of renal cell cancers can be explained by genetic predisposition.
  • [MeSH-major] Carcinoma, Renal Cell / genetics. Cell Transformation, Neoplastic / genetics. Kidney / pathology. Kidney Neoplasms / genetics. Neoplastic Syndromes, Hereditary / genetics
  • [MeSH-minor] Adenocarcinoma, Clear Cell / genetics. Adenocarcinoma, Clear Cell / pathology. Adenoma, Chromophobe / genetics. Adenoma, Chromophobe / pathology. Adenoma, Oxyphilic / genetics. Adenoma, Oxyphilic / pathology. Carcinoma, Papillary / genetics. Carcinoma, Papillary / pathology. Cell Lineage. Cell Transdifferentiation. Genes, Tumor Suppressor. Hematopoietic Stem Cells / pathology. Humans. Kidney Glomerulus / pathology. Mutation. Neoplasm Proteins / genetics. Neoplasm Proteins / physiology. Oncogenes

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 1997 Sep;158(3 Pt 1):724-8 [9258068.001]
  • [Cites] Proc Natl Acad Sci U S A. 1971 Apr;68(4):820-3 [5279523.001]
  • [Cites] Radiology. 2003 Jan;226(1):33-46 [12511666.001]
  • [Cites] Nature. 1991 Jun 6;351(6326):453-6 [2046748.001]
  • [Cites] Cancer Res. 1994 Jul 15;54(14):3710-3 [8033088.001]
  • [Cites] Kidney Int. 2002 Feb;61(2):387-95 [11849378.001]
  • [Cites] J Pathol. 1999 Sep;189(1):105-11 [10451496.001]
  • [Cites] Hum Mutat. 1996;8(4):348-57 [8956040.001]
  • [Cites] Mayo Clin Proc. 2000 Mar;75(3):265-72 [10725953.001]
  • [Cites] Int J Cancer. 1989 Mar 15;43(3):422-7 [2925273.001]
  • [Cites] J Med Genet. 1991 Jul;28(7):443-7 [1895313.001]
  • [Cites] Nat Genet. 1997 May;16(1):68-73 [9140397.001]
  • [Cites] J Natl Cancer Inst. 1989 Jul 19;81(14):1097-101 [2738940.001]
  • [Cites] Oncogene. 1997 Mar 6;14(9):1093-8 [9070658.001]
  • [Cites] Am J Pathol. 2001 Sep;159(3):825-9 [11549574.001]
  • [Cites] Cancer Genet Cytogenet. 1984 Apr;11(4):479-81 [6704944.001]
  • [Cites] Semin Oncol. 2000 Apr;27(2):138-49 [10768593.001]
  • [Cites] Lab Invest. 1987 Jun;56(6):642-53 [2439772.001]
  • [Cites] Am J Hum Genet. 1998 Jun;62(6):1475-83 [9585616.001]
  • [Cites] Arch Dermatol. 1977 Dec;113(12):1674-7 [596896.001]
  • [Cites] Urology. 2002 Dec;60(6):941-6 [12475646.001]
  • [Cites] J Urol. 1998 Aug;160(2):335-40 [9679872.001]
  • [Cites] Nat Rev Cancer. 2004 May;4(5):381-93 [15122209.001]
  • [Cites] J Urol. 1989 Nov;142(5):1364-8 [2810532.001]
  • [Cites] Hum Pathol. 1988 Aug;19(8):980-7 [2456980.001]
  • [Cites] Histopathology. 2001 Nov;39(5):455-62 [11737302.001]
  • [Cites] Hum Mutat. 1995;5(1):66-75 [7728151.001]
  • [Cites] J Urol. 1995 Jan;153(1):22-6 [7966777.001]
  • [Cites] Cancer Cell. 2005 Aug;8(2):143-53 [16098467.001]
  • [Cites] Development. 1998 Sep;125(17):3313-22 [9693135.001]
  • [Cites] Cancer Genet Cytogenet. 1995 May;81(1):72-5 [7773963.001]
  • [Cites] Anticancer Res. 1996 Nov-Dec;16(6B):3807-11 [9042262.001]
  • [Cites] Int J Biochem Cell Biol. 1997 Jan;29(1):55-62 [9076941.001]
  • [Cites] Cancer Cell. 2002 Aug;2(2):157-64 [12204536.001]
  • [Cites] Cancer. 1988 Nov 1;62(9):1946-51 [2458824.001]
  • [Cites] J Med Genet. 1993 Feb;30(2):104-7 [8445612.001]
  • [Cites] Nat Genet. 1998 Sep;20(1):66-9 [9731534.001]
  • [Cites] Adv Cancer Res. 1993;62:89-124 [8109322.001]
  • [Cites] Cancer Res. 1995 Dec 15;55(24):6189-95 [8521412.001]
  • [Cites] N Engl J Med. 1979 Sep 13;301(11):592-5 [470981.001]
  • [Cites] Nature. 1988 Mar 17;332(6161):268-9 [2894613.001]
  • [Cites] Am J Clin Pathol. 2004 Jun;121(6):878-83 [15198361.001]
  • [Cites] Kidney Int. 1994 Feb;45(2):314-9 [8164414.001]
  • [Cites] Histopathology. 1993 Feb;22(2):135-9 [8454257.001]
  • [Cites] J Pathol. 1994 May;173(1):39-44 [7931836.001]
  • [Cites] J Urol. 1994 Mar;151(3):561-6 [8308957.001]
  • [Cites] J Urol. 1996 Jul;156(1):281-5 [8648824.001]
  • [Cites] Science. 1993 May 28;260(5112):1317-20 [8493574.001]
  • [Cites] J Urol. 1985 Mar;133(3):502-5 [3883008.001]
  • [Cites] Blood. 1991 Dec 1;78(11):2848-53 [1720038.001]
  • [Cites] Br J Cancer. 1994 Feb;69(2):230-4 [8297719.001]
  • [Cites] Histopathology. 1987 Feb;11(2):157-70 [2437002.001]
  • [Cites] Science. 1991 Feb 15;251(4995):802-4 [1846706.001]
  • [Cites] Cancer Res. 1993 Dec 1;53(23):5780-3 [8242636.001]
  • [Cites] Pathol Res Pract. 1997;193(4):299-304 [9258956.001]
  • [Cites] J Urol. 1995 Mar;153(3 Pt 2):907-12 [7853572.001]
  • [Cites] Int J Cancer. 1997 Jul 17;72(2):265-9 [9219831.001]
  • [Cites] Kidney Int. 1999 Oct;56(4):1455-67 [10504497.001]
  • [Cites] Oncogene. 1997 Sep 25;15(13):1583-6 [9380410.001]
  • [Cites] Cancer Res. 1989 Dec 15;49(24 Pt 1):6972-5 [2582439.001]
  • [Cites] JAMA. 1995 Feb 15;273(7):564-70 [7837390.001]
  • [Cites] Cancer Treat Res. 2003;116:3-27 [14650823.001]
  • [Cites] Cancer. 1996 Mar 15;77(6):1154-60 [8635138.001]
  • [Cites] Cancer Genet Cytogenet. 1990 Apr;45(2):197-205 [2317768.001]
  • [Cites] J Am Soc Nephrol. 1992 Apr;2(10 Suppl):S190-7 [1600136.001]
  • [Cites] Am J Surg Pathol. 2001 Dec;25(12):1485-92 [11717537.001]
  • [Cites] Cancer Res. 1995 Feb 1;55(3):658-62 [7834636.001]
  • [Cites] Int J Cancer. 1996 Jun 21;69(3):212-7 [8682590.001]
  • [Cites] Cancer Res. 1998 Jan 15;58(2):226-31 [9443397.001]
  • [Cites] Curr Opin Nephrol Hypertens. 2001 May;10(3):315-20 [11342792.001]
  • [Cites] Am J Surg Pathol. 2002 Dec;26(12):1542-52 [12459621.001]
  • [Cites] EMBO J. 1990 May;9(5):1595-602 [1691710.001]
  • [Cites] Cancer Res. 1989 Jul 1;49(13):3627-30 [2659164.001]
  • [Cites] J Natl Cancer Inst. 1972 Feb;48(2):313-24 [4347033.001]
  • [Cites] Cancer Res. 1990 Aug 1;50(15):4504-9 [1973362.001]
  • [Cites] Arch Pathol Lab Med. 1986 Sep;110(9):825-32 [3530188.001]
  • [Cites] Am J Pathol. 1996 Dec;149(6):2089-94 [8952541.001]
  • [Cites] J Urol. 1999 Oct;162(4):1246-58 [10492174.001]
  • [Cites] Am J Clin Pathol. 1986 Jun;85(6):724-31 [2422924.001]
  • [Cites] Am J Surg Pathol. 2004 May;28(5):676-8 [15105658.001]
  • [Cites] Genomics. 1990 Dec;8(4):634-40 [2276737.001]
  • [Cites] Am J Hum Genet. 2001 Oct;69(4):876-82 [11533913.001]
  • [Cites] Nephrol Dial Transplant. 1999 Dec;14(12):2860-72 [10570089.001]
  • [Cites] Eur Urol. 2003 Jun;43(6):680-5 [12767370.001]
  • [Cites] Int J Cancer. 1987 Aug 15;40(2):171-8 [3610386.001]
  • [Cites] Cytogenet Cell Genet. 1996;75(2-3):180-5 [9040788.001]
  • [Cites] J Pathol. 1997 Oct;183(2):151-5 [9390026.001]
  • (PMID = 19015066.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Neoplasm Proteins
  • [Number-of-references] 94
  •  go-up   go-down






Advertisement